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This chapter is a compilation of four different studies using the same data set but with a 
different research question. Each part has its own objective, methods, and results. 
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Improving adherence to appropriately prescribed medications enhances clinical 
outcomes. To our knowledge, there is scarce literature on the implementation and 
outcomes of an adherence support service when provided as “routine” or real-world care. 
Determination of the adherence level within the large population is challenging and 
increasing access to administrative data can be useful to face this challenge. The aim of 
this thesis was to determine medication adherence, to study factors influencing 
adherence, and to determine the influence of a medication use review (MUR) service on 
adherence. 
Methods 
This thesis used centrally-held dispensing data (Pharmhouse) to determine the 
medication adherence by estimating the proportion of days covered (PDC) in patients 
taking oral hypoglycaemics (OHG). The influence of patient demographics, type of 
therapy, and co-dispensing (polypharmacy) on adherence was evaluated. In a separate 
study MUR records were analyzed to determine the medication adherence which was 
then correlated to the clinical biomarkers from pathological report.      
Results 
Within the study region, 54.5% of patients receiving OHG were non-adherent (PDC < 
80%). Non-adherence was significantly higher in men, NZ Māori ethnic group, young and 
middle ages (21 to 60 years) and low income group. Based on the type of therapy i.e. 
monotherapy, a combination of two and a combination of three OHG, the non-adherence 






elder patients (age 61 years and above). Based on the polypharmacy status i.e. Non-poly, 
Poly with 5, Poly with 6, Poly with 7, Poly with 8, Poly with 9 and Excess polypharmacy 
(10 or 10+), the non-adherence (PDC < 80%) was found to be 60.9%, 49.5%, 46.8%, 
47.7%, 41.8%, 43.1% and 37.5% respectively. People with high adherence (MUR score 
3/4) had decreasing HbA1c or lipid levels and conversely, the people with poor 
adherence (MUR score 1/2) continued to show an increase in HbA1c or lipid levels with 
time. 
Discussion 
Non-adherence is a preventable public health burden if identified, and corrected early. 
Therefore, identification of medication non-adherence (prevalence, nature and cause) is 
the most important step for developing the strategies for adherence improvement. The 
observation from this thesis reporting non-adherence (PDC <80%) in 54.5% patients 
taking OHG was consistent with other published studies. Gender, ethnicity, and 
socioeconomic status had a significant influence on the rate of non-adherence. Many 
published studies from the literature have reported non-adherence in patients with 
polypharmacy. Contrary to these studies, this thesis observed that there was higher 
adherence in patients with polypharmacy. This thesis has investigated the impact of a 
structured adherence service when offered in a “real life” setting and indicated that for 
those patients who had follow-up visits, adherence was improved. Importantly there was 
a positive impact of this adherence on clinical biomarkers such as HbA1c and lipid profile. 
Compiling data on dispensing records and hospitalization information may allow longer-









The pharmacy dispensing records can be used to identify the patients with medication 
non-adherence so that the adherence improvement strategies can be implemented. 
Pharmacists performing an adherence support service can positively influence 
medication adherence and clinical outcomes. 
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1. Introduction and Literature Review 
1.1 Diabetes mellitus  
The worldwide prevalence of diabetes is increasing rapidly; it is estimated that around 
642 million people will have diabetes by 2040 [1]. In the Global Burden of Disease Study 
2013, diabetes was reported to be the ninth major disorder that reduces expectancy of 
patient life [2]. The number of diabetes mellitus cases has increased four-fold between 
1980 to 2014 [3]. In the year 2015, China was on the top (109.6 million), India was second 
(69.2 million) and the USA ranked third-highest (29.3 million) in the world for the 
existence of diabetes mellitus in adults (20–79 years) [1]. The Pacific nations also exhibit 
a high prevalence of diabetes mellitus; >30% in American Samoa and 25% in some other 
islands in Polynesia and Micronesia [3]. 
The incidences of being undiagnosed were found in 45.8% (i.e. 174.8 million cases) of all 
global diabetes cases [4] and such cases are most vulnerable to complications than others 
who are getting treatment [5]. Globally, 85-95% of diabetes cases are considered to be 
Type 2 diabetes mellitus (T2DM) [6]. The incidence of adolescent T2DM (in the 10-19 
years of age) was particularly high in the indigenous people of Australia, the USA, and 
Canada, as compared to other population [7,8,9]. 
1.1.1 Etiology of T2DM 
In T2DM, abnormal glucose levels in the blood are due to a deficient feedback mechanism 
between insulin secretion and insulin action, which leads to diminished insulin secretion 
by pancreatic β-cells of the Islets of Langerhans and aggravated insulin resistance 
(predominantly in insulin-sensitive tissues such as muscle, adipose tissue, and liver) 
(Figure A) [5,10,11]. The higher than normal blood glucose level (hyperglycemia) and 
higher HbA1c levels are biological manifestations of T2DM [10]. 






Figure A: Pathophysiology of hyperglycemia in T2DM [5] 
Sedentary lifestyle, aging, hereditary factors, and obesity incidences are strongly linked 
with insulin resistance [12,13,14]. 
Major factors associated with the risk of T2DM [5,12,13,14]: 
1. Being overweight or obese (Body Mass Index, BMI ≥25kg/m2) 
2. A family history of Type 2 diabetes mellitus 
3. Older age 
4. Low socioeconomic status 
5. Non-white ancestry 





6. Components of the metabolic syndrome (low plasma levels of high-density 
lipoprotein (HDL) cholesterol, increased plasma levels of triglycerides, increased 
blood pressure, and increased waist circumference) 
7. Diet and lifestyle factors (diet, physical activity, smoking, alcohol intake) 
8. Genomics and gene-environment interactions 
9. Psychosocial stress and depression 
1.1.2 Obesity and diabetes 
High BMI indicating obesity leads to insulin resistance and increases the risk of T2DM. 
[15,16,17] Low physical activity and junk food habits (eating energy-dense food) are also 
crucial factors associated with obesity and T2DM [14,18]. By 2050, the worldwide 
prevalence of obesity in men and women could reach up to 18% and 21% respectively 
[19]. Visceral adiposity [20] and weight put on at adolescence, with a regular gain from 
middle age [21], both independently predict the risk of T2DM. 
1.1.3 Diet and diabetes 
Development of T2DM is positively linked with excess consumption of sugar 
(carbohydrate) or white rice [22,23]. Researchers have established a link between 
impaired glucose tolerance and a high-fat diet [24,25]. Insulin resistance increased with 
high consumption of fried foods, red meat and sweets can lead to T2DM [26]. Obesity was 
evident in people with regular intake of soft drinks (being a source of high fructose corn 
syrup) [27]. Glycated chemicals present in diet soft drinks increases insulin resistance 
[28]. 
  





1.1.4 Lifestyle and diabetes 
The risk of T2DM is directly linked with the time spent being sedentary [12,29]. A meta-
analysis reported that there is a 45% higher risk of developing T2DM in smokers than 
non-smokers [30]. A prospective study has linked high levels of passive smoke to T2DM 
development [31]. Central fat deposition tendency is likely to be high in smokers and that 
may lead to insulin resistance [32]. A lower educational level and a low socioeconomic 
status can be linked with T2DM [5,33]. 
1.1.5 Diabetic complications 
Independent predictors of macrovascular complications are high cholesterol, smoking, a 
sedentary lifestyle, male gender, and aging and those of microvascular complications are 
the duration of diabetes over 10 years, hypertension and smoking [34]. Persistent 
hyperglycemia causes microvascular complications but macrovascular complications are 
due to persistent hyperglycemia associated with hypertension, dyslipidemia and 
smoking [34,35]. Diabetic peripheral neuropathy, diabetic retinopathy, diabetic 
autonomic neuropathy and diabetic nephropathy are microvascular complications that 
may lead to diabetic morbidity, while diabetic mortality can be caused by macrovascular 
complications including cerebrovascular disease, peripheral vascular disease and 
coronary heart disease [34,35,36,37]. T2DM patients are at increased risk of premature 
cardiovascular disease as most of them exhibit hyperinsulinemia, hypertension, and 
dyslipidemia [37]. 
1.1.6 Diabetes and mortality 
Estimated diabetes deaths worldwide in 2010 were reported to be 3.96 million and in 
2015 the count was increased to 5.0 million diabetes deaths (hypothetically one death 
per six seconds) [1,38]. Different vital organ(s)/systems are affected by diabetic 





complications as hyperglycemia is strongly related to the risks of microvascular events, 
stroke, myocardial infarction and lethal outcome [39,40]. Death due to cerebrovascular 
disease (15%), renal disorder (10 to 20%) and cardiovascular defects (52-80%) has been 
observed in T2DM patients [41,42].  
1.1.7 Management of T2DM 
The effects of the ‘ominous octet’ causing hyperglycemia can be altered with the 
introduction of hypoglycemic agents (i.e. pharmacological management of T2DM) [43].  
Currently available hypoglycemic agents target one or more of following 
pathophysiological mechanisms to achieve glycemic control [44]: 
1. Reduced insulin secretion from pancreatic β cells,  
2. Increased glucagon secretion from pancreatic α cells,  
3. Increased hepatic glucose production,  
4. Neurotransmitter dysfunction and insulin resistance in the brain,  
5. Increased lipolysis,  
6. Increased renal glucose reabsorption,  
7. Reduced incretin effect in the small intestine and  
8. Reduced glucose uptake in peripheral tissues such as skeletal muscle, liver, and 
adipose tissue  
Commonly used oral hypoglycemic agents are biguanides (e.g. metformin), sulfonylureas 
(e.g. gliclazide, glipizide, glibenclamide, tolbutamide), thiazolidinediones (e.g. 
pioglitazone, rosiglitazone), meglitinides (e.g. repaglinide, nateglinide), alpha-
glucosidase inhibitors (e.g. acarbose, miglitol), incretin agonists (e.g. exenatide, 





liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g. sitagliptin, vildagliptin, 
saxagliptin) [45, 46].  
1.1.8 Economic burden of diabetes 
In comparison to the general population, the treatment cost of diabetes is three-fold 
higher [47]. Patients paying for the treatment out of their own pocket can experience a 
significant burden as a large part of the income is spent on diabetes therapy 
[48,49,50,51,52]. This burden was relatively high in patients with financial hardship due 
to low income [52,53,54]. The global medical expenses for treating diabetes and related 
complications were estimated US$673 billion for the year 2015 alone [1]. One study 
reported that treatment cost of the diabetes mellitus (excluding complications) 
inpatients in Malaysia, China, Thailand, and India was 11–75% of the per-capita income 















1.2 Medication adherence 
The World Health Organization (WHO) defined medication adherence as “the extent to 
which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care provider” [56]. The 
patients failing to follow such recommendation are referred as non-adherent [56,57].  
It has been 50 years since the first published study on adherence and still researchers 
and healthcare professionals are facing the challenge of improving medication adherence 
[58,59]. Treatment failure or sub-therapeutic outcomes raised healthcare costs and 
increased use of healthcare resources has been associated with poor medication 
adherence [60,61,62].  
‘Adherence to medications’ indicates the way patients follow the prescribed medication 
instructions, further divided into three quantifiable phases: ‘Initiation’, ‘Implementation’ 
and ‘Discontinuation’ [63]. 
By taking the first dose of a prescribed medication, a patient begins with treatment 
initiation. Next is implementation of the dosing regimen, measuring to what degree the 
prescribed dosing regimen matches with a patient’s actual dosage intake, from initiation 
until the last dose is taken. Omitting the subsequent dose and permanently quitting the 
medication thereafter results in discontinuation [63]. 
Non-adherence to medications can thus occur in the following situations or combinations 
thereof: late or non-initiation of the prescribed treatment, sub-optimal implementation 
of the dosing regimen or early discontinuation of the treatment [63].   
Apart from the patient behaviour there are other factors related to non-adherence, like 
socioeconomic status determining the affordability of medications (or determining 





accessibility of healthcare [64]), side effects of the drug, treatment duration, and 
complexity or the nature of disease [65]. Such and more factors are listed in Figure 1.2, 
which can affect medication adherence. All kinds of disease/disorder treatments possess 
a threat of medication non-adherence, particularly the chronic ones [66]. 
 
Figure 1.2: WHO, Five Interacting Dimensions Affecting Adherence [56,65]. 
 
There are two main categories of non-adherence: 
a. Primary non-adherence (affecting treatment ‘initiation’ phase) 
b. Secondary non-adherence (affecting treatment ‘implementation’ phase) 





1.2.1 Medication non-adherence 
1.2.1.1 Primary medication non-adherence (affecting treatment ‘initiation’ phase) 
A patient’s failure to collect an initial prescription of new medication is ‘primary 
medication non-adherence’ and can be considered as primary non-adherence [67,68]. 
Other terms used measuring exactly the same behaviour are “primary prescription 
noncompliance” [69], “initial noncompliance” [70], “first-fill adherence” [71], “nonfilling” 
[72], “unfilled prescriptions” [73,74] and “prescription abandonment” [75,76,77]. 
Primary medication non-adherence and prescription abandonment are relatively 
different terms based on the given circumstances. “Prescription abandonment” is when a 
prescription is filled by a pharmacy but not claimed by the patient. The instances of first-
fill abandonment, which is primary medication non-adherence, as well as the 
abandonment of refilled prescriptions, is not primary medication non-adherence but, 
rather, secondary non-adherence [68]. 
 
1.2.1.2 Secondary medication non-adherence (affecting treatment 
‘implementation’ phase) 
A patient failing to refill the prescription for the already started treatment is considered 
as secondary medication non-adherence [57,66,78]. Early discontinuation of therapy, 
missing doses or skipping doses can also attribute to secondary non-adherence [79]. The 
percentage of secondary non-adherence in chronic conditions is almost 50% and 
discontinuation after the first refill is seen in 20% of such cases [80,81]. Pharmacy 
administrative data is useful to measure secondary non-adherence because it quantifies 
medication adherence based on prescription refill, which assumes that the consumption 





of the drug is exactly as prescribed [82]. This assumption is well accepted in adherence 
research [83]. Many adherence studies reported evaluating secondary non-adherence 
[82,83,84,85,86,87,88,89,90,91]. Ready access to a large population’s individual record is 
the main advantage of adherence studies using pharmacy data [92]. 
 
1.2.2 Quantification of medication non-adherence  
List of different measures to determine secondary medication non-adherence [83,85,92]: 
1. Continuous Measure of Medication Acquisition (CMA) 
2. Continuous Measure of Medication Gaps (CMG) 
3. Continuous Multiple Interval Measure of Oversupply (CMOS) 
4. Compliance Ratio (CR) 
5. Continuous, Single Interval Measure of Medication Acquisition (CSA) 
6. Days Between Fills (DBR) 
7. Medication Possession Ratio (MPR) 
8. Medication Refill Adherence (MRA) 
9. Proportion of Days Covered (PDC) 
10. Refill Compliance Rate (RCR) 
The Proportion of Days Covered (PDC) and the Medication Possession Ratio (MPR) are 
the two most commonly used measures to estimate medication adherence from 
secondary databases (e.g. electronic dispensing data or claims data) 
[85,93,94,95,96,97,98]. Hence only PDC and MPR as an adherence measure are discussed 
in this thesis and not the other measures listed above. 






Figure 1.2.2: Sample calculations of MPR & PDC [98]. 
1.2.2.1 Medication possession ratio (MPR) 
[67,85,87,88,89,93,94,99,100,101,102,103,104] 
MPR is generated as a ratio of a number of days in which the patient has the medication 
available according to prescription divided by the days in the observation period (Figure 
1.2.2). The resultant value can be multiplied by 100 to obtain a percentage of MPR. 
Medication availability can be measured for the multiple (total) time intervals or single 
interval [89]. Values greater than 100 indicates “oversupply” which can be truncated to 
100. Oversupply is common in patients with chronic conditions as they have a tendency 
of bulk dispensing or early refills [67,88].  
MPR calculations are simple but fail to acknowledge any gaps in refills resulting in 





Here total days’ supply gives the number of days for which patient had the medications 
collected & “365” is the observation period. 





In the case of combination therapies (dual/triple) the MPR can be calculated as follows: 
MPR (dual/triple therapy) =





1.2.2.2 Proportion of days covered (PDC) [105,90,91,106,107,108,109,110]  
The formula for the PDC calculation is the same as that of MPR but instead of considering 
the total days’ supply as it is, PDC considers the days “covered” (Figure 1.2.2). E.g. in a 
case of early refill the days overlapping will be excluded, or in combination therapy, the 
presence of all the medication on the same day will be considered as days covered. PDC 






Here, total days’ covered gives the number of days for which patient had the medications 
collected excluding overlapping days due to early refill, and “365” is the observation 
period. 
In the case of combination therapies (dual/triple) the PDC can be calculated as follows: 
PDC (dual/triple therapy) =
Total days’ covered 











Summary of MPR & PDC 
 
Table 1.2.2: Strength and weakness of MPR & PDC.  
Characteristics MPR PDC 
Strengths   
Categorical or continuous X X 
Ease of calculation X  
Overall study adherence generated if 
averaged for each patient across the study 
period 
X X 
Early refill days can be considered (adjusted)  X 
Robustness of the method  X 
Weakness   
Multiple calculation methods in literature 
create confusion 
X  
Required minimum of two scripts 
(dispensing dates/observations) for 
adherence calculations 
X  
Improved precision when calculated over at 
least 3 dispensing 
X X 
Symbol “X” marks the presence of the respective characters in the given measure 
1.2.2.3 Advantage of PDC over MPR for adherence estimation  
MPR is calculated by adding the days’ supply for all medications and then dividing over a 
certain period of time. It assumes that all drugs eventually get used within the time 
period, which may overestimate the actual adherence if patients refill their medication 
before the last date of the preceding prescription. In contrast to MPR, PDC looks at each 
day to determine if the patient has one or more dispensed drugs and then determines the 
proportion of days that a patient has a drug available in a study interval. The medication 





possession ratio (MPR) reflects the patient’s overall accordance with the prescribed 
dosing regimen and disregards the timeliness of particular refills. Theoretically, PDC 
more accurately reflects patient adherence behaviour, and it more effectively handles 
drug switching and prescription overlaps [88,98]. Pharmacy Quality Alliance (PQA) and 
The Centres for Disease Control and Prevention (CDC) are the recognized institutes in the 
USA working for public health benefits and promoting appropriate medication use. Both 
of them recommended PDC for medication adherence calculation at the population level 
as a validated and time-tested quality measure [106]. 
1.2.2.4 Limitation of the secondary database for medication adherence analysis 
Medication possession does not guarantee the consumption of medication. MPR/PDC 
based on pharmacy administrative data may not be able to determine treatment initiation 
non-adherence or discontinuation as they are effective in evaluating treatment 
implementation or persistence.   The accuracy of the data source is important for reliable 













1.2.3 Factors related to medication non-adherence  
Factors related to primary medication non-adherence: 
1. Healthcare system related factors 
2. Therapy related factors 
3. Patient related factors 
4. Socioeconomic Factors 
5. Condition (disease/disorder) related factors 
1.2.3.1 Healthcare system related factors in primary medication non-adherence 
Patient education and counseling, reputation and experience of healthcare professional, 
physician-patient bonding (trust, shared decision making, conveyance) are the 
healthcare provider factors. Lack of communication leading to primary non-adherence 
was observed in most studies [111,112,113,114,115]. In such case, patients may lose 
their faith in diagnosis by a health professional and get demotivated to start therapy 
[113]. On the contrary, the welcoming and comfy engaging behaviour of healthcare 
professional encouraged the patients to obtain their medication on time [111]. 
Prescriptions from experienced (10 or more years) physician may have high rates of 
collection from pharmacy [116]. Patients consulting a specialist were more likely to fill 
their prescription than those seeing a junior physician [117]. Hence, the reputation and 
experience of healthcare professionals can be strongly linked to primary non-adherence 
[57,116,117].  
1.2.3.2 Therapy related factors in primary medication non-adherence 
The comparative studies have reported that drug types have a potential role in primary 
non-adherence [105,118,119,120,121,122] e.g. one Portuguese study reported that the 





primary non-adherence was higher in patients with antidiabetic medication than those 
with antihypertensives [121].   
Complex/multiple medication regimen and polypharmacy was reported as principal 
cause of primary non-adherence [120,78,123,124,125]. Medication unaffordability also 
contributed to primary non-adherence [118,120,78126].  
1.2.3.3 Patient related factors in primary medication non-adherence 
Patient demographics, medical history, physical/mental health, health literacy, and 
attitudes/beliefs/perceptions are the factors related to primary medication non-
adherence. The predominant patient factor causing primary non-adherence was the 
perception of the patient about the treatment effectiveness and risk involved with 
prescribed medication [57].   
The primary non-adherence related demographics reported over different studies were 
not consistent. Many studies reported primary non-adherence in younger patients 
[112,119,120,78,123,127,128] whereas a few studies also mentioned the presence of 
primary non-adherence in older adults [66,124,129]. As compared to men, the primary 
non-adherence was higher in female patients [119,121,127,128,128,130]. Minority 
status or ethnicity/race also contribute to primary non-adherence. In the United States, 
minority patients (i.e. Hispanic and African American) were found to be more non-
adherent than white Americans [111,112,117,118,128].  
1.2.3.4 Socioeconomic factors in primary medication non-adherence 
Socioeconomic status has a huge influence on primary non-adherence as medication 
unaffordability is obvious with a low level of income [111,114,121,125,127,131]. Some 
studies have reported higher primary non-adherence in older patients [78] or elderly 





female patients [131] with lower socioeconomic background, suggesting that patient 
factors and low income goes hand in hand. Transportation limitation posed by financial 
hardship may restrict the patients from filling their prescription [125]. Primary non-
adherence and cost of medication are directly linked as treatment unaffordability is 
present in low earning patients [118,120,78,126]. 
1.2.3.5 Condition (disease/disorder) related factors in primary medication non-
adherence 
Condition-related factors represent particular illness-related demands faced by the 
patient. Some strong determinants of adherence are those related to the severity of 
symptoms, level of disability (physical, psychological, social and vocational), rate of 
progression and severity of the disease [56]. E.g. diabetic neuropathy and diabetic ulcers 
may impede a patient’s ability to pick up their medications. 
 
1.2.4 Other measures of medication adherence  
Both clinical and research settings demand accurate adherence measurement; failure to 
do so may increase the cost of treatment and pose threat to patient’s life. Costly advanced 
diagnostic tests may be ordered with an incorrect estimate of adherence and there might 
be an intensification of treatment which is unnecessary [83]. Adherence information is 
essential for proper interpretation of clinical trial results, because patients marked with 
poor adherence may produce false outcomes about drug-dose-response and ultimately 
report wrong treatment efficacy [84].  Medication adherence improvement strategies can 
be influenced by correct estimates of adherence as they can be linked to vital information 
about biomarkers and progression of disease/disorder.  





Acceptable adherence parameters need to be delineated and appropriated for patient 
circumstances and this makes adherence measurement more challenging [132]. Despite 
the availability of different methods for adherence estimation, there is no gold standard. 
Every method has its own advantage and drawback as it is based on the source of data 
and conditions of data collection. For accurate adherence measurement, these methods 
should be reliable, change sensitive and validated [132,133].     
WHO has classified adherence measurement as subjective and objective [56]. Evaluation 
of medication adherence behaviour of the patient by a health professional or by the 
patient himself is a basis of subjective measurements, where a questionnaire about 
medication-taking behaviour generates an adherence report of the individual [134]. Such 
assessment collects prospective as well as retrospective information about timing, 
patterns, and frequency of non-adherence [135]. Self-reported adherence can be biased 
as patients may hide non-adherence information to get approval from healthcare 
providers [135,136]. Such cases may represent an overestimation of adherence [136]. 
Biochemical measures, electronic monitoring, secondary database analysis, and pill 
counts are the objective measures [133,134]. Such measures can be used to correlate the 
subjective ones. These measures also have limitations as discarded pills may influence 
pill count or there may be mechanical malfunctions in electronic monitors [135].  
1.2.4.1 Biochemical/direct measures 
In such measures, body fluids like urine or blood will be evaluated for the presence of a 
drug or its metabolites. These measures can be performed at specific time intervals or 
randomly. The medication adherence is directly linked to the concentration of drug 
(biomarker) [84]. Despite being the most accurate measure there are limitations for the 
use of these measures. Firstly, they are expensive and involve many professionals and 





laboratory experts performing and monitoring the tests. They can’t evaluate the pattern 
of non-adherence as they create only Yes / No results [84]. The biological variation in 
individuals may influence the metabolic rate and alters the concentration of metabolites 
from the same drug in the different patient. Additionally, the slow elimination of a few 
drugs may result in their presence being detected in the body even long after quitting the 
drug. The drug assay’s accuracy can also be affected by drug-drug or food-drug 
interaction resulting in misleading adherence [137].           
1.2.4.2 Measures Involving Electronic Medication Packaging (EMP) Devices 
[84,138,139,140] 
Five common features of EMP devices and interventions are as following: 
1. Recording dosing events and storing a record of adherence 
2. Audio-visual reminders to cue dosing 
3. Digital displays 
4. Real-time monitoring 
5. Providing patients with adherence performance feedback 
The most commonly used EMP device is “Medication Events Monitoring System (MEMS)”. 
This device works by an embedded microprocessor which records the date and time 
whenever the medication is taken from a container. MEMS is able to record the count of 
the daily dose. MEMS is superior to self-reporting and biochemical assays as it can 
identify unusual medication consumption patterns or the nature of non-adherence 
(consistent/sporadic). Medication adherence overestimation is possible with MEMS as 
the patient may accidentally open the container without actually consuming the 





medication.  Despite being accurate in adherence estimation, the expensive nature of this 
device (MEMS) restricts its use in the larger population.  
1.2.4.3 Pill count [84,136,141,142] 
Defined as “A pill count is simply counting the number of dosage units (eg, tablets, capsules) 
that the patient has not taken by the scheduled appointment or clinic visit” [84]. 
Following equation generates the adherence ratio using pill count: 
Number of dosage units dispensed −  number of dosage units remaining
Prescribed number of dosage unit per day ×  number of days between 2 visits
 
Such a measurement is simple, self-explanatory and economical but not free from 
disadvantages. Adherence underestimation is common with pill count for the patients 
with chronic conditions as they have a habit of early refill (or bulk dispensing). Pill count 
won’t be able to inform about any medication-taking pattern or non-adherence pattern 













1.3 Management of adherence 
Management of adherence is the process of monitoring and supporting patients’ 
adherence to medications by health care systems, providers, patients, and their social 
networks. The objective of management of adherence is to achieve the best use by 
patients, of appropriately prescribed medicines, in order to maximize the potential for 
benefit and minimize the risk of harm [63]. 
1.3.1 Interventions for improving medication adherence 
Medication non-adherence can have inimical effects on public health which can be 
impeded with adherence improvement. There are research articles reporting the 
different tools to enhance medication adherence [63,143,144,145,146,147]. The issue 
with the adherence intervention literature is that not all the articles assess adherence 
magnitude and its therapeutic benefits together [148,149]. A varied approach involving 
population health and precision medicine basis is needed for boosting medication 
adherence [148,150,151]. 
The following are the few interventions mentioned in the adherence literature: 
1. Self-management interventions 
2. Behavioural interventions 
3. Risk communication interventions 
4. Integrated care interventions 
5. Educational interventions 
6. Packaging and daily reminders 





1.3.1.1 Self-management interventions 
Lifestyle modification along with prescribed medication can help to achieve therapeutic 
goals in patients with chronic illness (e.g. diabetes or cardiovascular disease) [152,153]. 
Risk factors (insulin resistance, high blood pressure, glucose intolerance, high lipid levels, 
abdominal obesity) associated with metabolic syndrome can be kept under control with 
lifestyle modification [154,155]. Health professionals can help to create awareness about 
self-efficacy and autonomy of patients to control their disease [154,156,157].  
Definition: Financial incentives, patient education, and reminders are self-management 
interventions improving knowledge and health outcome in patients with chronic illness, 
namely, in terms of knowledge, self-efficacy, and health status [65]. 
Impact: Improved adherence to medication and appointments was reported with the use 
of short message service (SMS) on a mobile device [158].  
1.3.1.2 Behavioural interventions 
It is challenging to deal with patients’ attitudes towards their medications as every 
patient has discrete beliefs, socio-economic status and education level [159,160]. Due to 
the fear of being dependent on medication forever, the patient may skip the treatment 
altogether [57]; a few may be concerned about adverse effects [161]. A unique 
intervention method that fits across all patient types and various conditions does not 
exist [65,161]. The issue of medication non-adherence can be better approached with an 
understanding of motivation factors which help patients to stick to the treatment 
guidelines [161]. 
Mostly the therapies targeting behaviours, cognitions and dysfunctional emotions or 
cognitive–behavioural techniques are the interventions aiming for patient’s positive 





inclination towards treatment and overall well-being [162]. Other techniques are 
integrated pre- and post-hospitalization interventions, home visits and telephone follow-
ups [163,164,165]. 
Definition: Behavioural interventions aim to change individual behaviour in those 
aspects related to everyday life; in the case of adherence, they aim to modify patients’ 
behaviour toward treatment [166]. 
 Impact: Patient’s perception of treatment can be managed with behavioural 
interventions [166]. Improved adherence and drop-in treatment discontinuation with 
chronic therapy was achieved with pharmacist-led care interventions [167,168,169]. 
1.3.1.3 Risk communication interventions 
If a patient willingly avoids the recommended treatment, then it is considered as 
intentional non-adherence which can be characterized by dropping the daily dose or the 
number of drugs that the physician will consider inappropriate [161,170,171]. Risk 
perception is at the centre of medication non-adherence with intentional origin [172]. A 
patient’s concern about the adverse drug effects can impact the patient’s medication-
taking behaviour [173]. Both affective and cognitive approaches are important for 
understanding the multifaceted or intricate nature of risk perception [172,173]. The 
patient can be equipped with productive risk communication by healthcare providers to 
yield an informed/shared decision [173,174].  
Definition: These interventions engaged the patient in prescribing decisions by 
communicating why a medication was indicated, its risks and benefits, and the likely 
impact on the patient’s health [65, 173,174]. 





Impact: Use of educational videos, web-based tools or pamphlets as patient decision aids 
was found impressive in easing risk communication of health provider-patient and 
informed decision-making [175,176].   
1.3.1.4 Integrated care interventions 
Healthcare provider education, multidisciplinary clinical pathways and feedback, 
reminders, case management, structured clinical follow-up, patient education, and self-
management support are the commonly encountered objects of integrated care 
intervention [177]. Reinforced healthcare complacency and coherence for both the 
patients with an intricate health issue and care providers can be achieved with the 
integrated care interventions [178,179]. Care management or integrated care is an 
institutional model and set of expertise to strengthen alignment, cooperation, and 
connectivity between and within healthcare professionals [180].  
Definition: Integrated care has been defined in various studies as a group of techniques 
and organizational models to enhance connectivity, alignment, and collaboration within 
and between health care providers at different levels (funding, administrative, and/or 
provider) [180]. 
Impact: Close cooperation within interdisciplinary teams of healthcare providers creates 
a positive impact that may shorten the hospital stay or lower the hospitalization risk with 
the implementation of care management plans [181,182,183].  
1.3.1.5 Educational interventions 
Patient education is one of the core objectives of patient-centred care [65]. Patients 
getting informed and communicated with about the disease and its pharmacological 
treatment can be advantageous to improving medication adherence [65,174]. Adherence 





literature shows a wide use of patient education to compel medication adherence, and it 
has achieved a status of the prime domain in medicine [184,185,186,187,188,189,190]. 
Definition: The education intervention executed by [191]: 
- discussing with patients their faith and understanding of their health or 
disease and corresponding therapy 
- pointing out and consulting with patients any disinclination to take 
medicines 
- properly instructing the patient about medication consumption 
Impact: Patient education as a stand-alone intervention may not improve medication 
adherence or treatment outcomes, but may improve patient knowledge [65]. Patient 
education in association with patient counselling by pharmacist or self-management 
skills training, has a positive impact in adherence and in other clinical outcomes and 
knowledge, but results are not consistent [65,185,186]. 
1.3.1.6 Packaging and daily reminders 
Achievement of improved medication adherence and clinical outcomes with the reminder 
packaging and various reminder tools has been reported in several studies 
[65,192,193,194,195,196,197,198,199,200,201,202,203]. For low literate patients, 
medication-taking can be aided with visual graphics presenting the time of day and how 
to take the pill [201,202,203]. Other widely-used reminder packagings are foil-backed 
blisters or prefilled medication boxes [201,202,203]. 
Definition: The reminder tools in packaging and daily reminders intervention, consisted 
of personalized blisters, medication boxes, interactive voice response (IVR) systems, 
reminder phone calls, pagers, text messages or video telephone calls [192]. 





Impact: All studies have shown that reminders in any variation and reminder packaging 
have a positive impact on medication adherence and often also on clinical results 
[65,192,193,194,195,196,197,198,199,200,201,202,203]. 
 
1.4 A summary of the different types of pharmacist-led medication review 
services [204,205,206] 
Table 1.4: Objective descriptions of type of medication review by pharmacists  
Service Characteristics 
Adherence review e.g. 
Medicines Use 
Review (MUR) [204] 
Addresses issues relating to a patients’ medication-taking 
behaviour, advice on medications use e.g. adverse effects, 
checking patients’ technique and use of medication dosage 
forms e.g. inhalers, identify need for a change in dosage form. 
Clinical medication 
review [205] 
Addresses issues relating to a patients’ use of medication in 
the context of their clinical condition such as the 
appropriateness, effectiveness, cost-effectiveness and 
monitoring required to meet the patient’s needs. 
The intervention must be face to face with the patient and it 




As explained for ‘Clinical medication review’, but pharmacist 
has the ability to prescribe or adjust the medication dose 










1.5 Medication Use Review (MUR) 
Desired therapeutic outcomes can be achieved by medication monitoring and 
recommended changes (when necessary) [207]. Drug use can be highly effective and safe 
with a professional collaboration of a pharmacist and a prescriber for medicines 
management role [208,209,210]. 
For optimal efficacy and safety and to ensure prescribed treatment is understood, New 
Zealand has introduced pharmacist-led patient-specific services [208]. The Pharmacy 
Council of New Zealand’s Medicines Management Competence Framework has 
highlighted four levels of services ranging from dispensing to undertaking 
comprehensive medicines management [208,209]. The National Pharmacist Services 
Framework 2014 groups the services as either medicines adherence services or 
medicines optimization services (Figure 1.4) [208,209]. 
 
 
Figure 1.4: Medicines management services in New Zealand [208,209]. 





A population with low socioeconomic status, living with mental illness and addiction or 
complex medication regime could gain benefits from pharmacist-led medicines 
management services [208,209,211,212]. Healthcare support for elderly people is 
essential in New Zealand as most of the population is aging (both those in residential care 
and those living in their own homes) [213]. Currently, there are three or more chronic 
illnesses present in New Zealand’s aging population (aged 65 years). Such services will 
help with overall wellbeing by improving medication adherence, and keeping people out 
of the hospital and delaying admission to residential facilities [208,209,212]. 
1.4.1 Medication Use Review and Adherence Support (MUR) service, New 
Zealand [208,209] 
In 2007, the government funded MUR service was introduced in New Zealand. However 
this service was only funded at an individual DHB level and so uptake across the country 
was not consistent.  
 
1.4.1.1 Aim 
To give a comprehensive, systematic, evaluation of a patient’s understanding of and 
adherence to prescribed treatment. The pharmacist aims to improve understanding of 
and adherence to medicines, identifying and addressing factors linked to non-adherence 
behaviours as well as minimizing pharmaceutical waste. 
 
1.4.1.2 The goal for the patient 
1. Targeted intervention for patients suffering from chronic illness to educate them 
about their medication (how to take them and what for) 





2. Integrated prescriptions and modified dosing frequency as per the patient's 
requirement and capacity 
3. The pharmacist provided support for a) medication concerns, b) access to and 
administration of medicines and c) medication adherence 
 
1.4.1.3 The goal for the prescriber/healthcare system 
1. Improving medication adherence and patient’s understanding of complex 
treatment regimen especially in the case of patients with lower literacy or the 
addition of a new drug with high-risk 
2. Shared decision making with patients to develop a consensual plan of action to 
identify the behaviour, and beliefs causing medication non-adherence 
 
1.4.1.4 Accreditation of MUR pharmacist in New Zealand 
An MUR pharmacist must successfully complete the Medicines Use Review training and 
accreditation formally assessed against Pharmacy Council Medicines Use Review 
standards [208]. Additionally, MUR pharmacists require knowledge and skills in 
behavioural change management. 
 
1.4.1.5 Eligibility for enrolment 
Patients are living independently in the community, having one or more chronic disease 
states and meeting one or more of the following conditions: 
 Medication change after discharge from hospital 
 Prescribed multiple medications (three or higher) and or daily doses 12 or 
higher 
 Have multiple prescribers 





 Taking medicines with a narrow therapeutic range  
 If suspected or present with the medicine-related problem (e.g non-adherence, 
adverse reaction) 
 Have impaired sight, dexterity problems, cognitive deficiencies, literacy or 
language difficulties that can affect their medication management abilities 
 
1.4.1.6 MUR service referrals or linkages in New Zealand 
A patient can self-refer to MUR services. Other referral may be from different healthcare 
professionals including prescribers, primary healthcare nurses, nurse practitioners, 
hospital or primary-secondary care liaison pharmacists, community pharmacist, and 
any/other healthcare providers. 
 
1.4.1.7 MUR service setting in New Zealand 
 Community Pharmacy 
 Hospital Pharmacy 
 PHO/Integrated Health-based Pharmacists 
 Private consultant practitioners 
 Service may be delivered in other settings (e.g. Patient’s home, marae, ‘clinics’) 
 
1.4.1.8 MUR service reporting 
The patient-pharmacist interview meeting will be documented with the help of MUR form 
reporting about a) demographics of patient, b) the reason for service enrolment, c) 
current medication list, d) any adverse effects or therapeutic issue, e) the medication 
adherence and f) comments for changes in the prescription (if required). 





1.4.1.9 MUR service activities/outputs [208,209] 
1. Medicines information: understanding the dispensing habits and advice based 
on it.  
2. Medicines reconciliation: documenting any variation and medication 
reconciliation if prescribed medication is not matching with current medication, 
adverse drug events, and allergies. 
4. Synchronization: integrated prescriptions along with regular medicine’s supply 
and modified dispensing as per the changes in the treatment regimen by 
prescribers.        
3. Reminders: individualized service and technology used to target patient 
adherence. 
4. Adherence support: encouraging patients to adhere to the recommended 
therapy and effectively handle the changes to a prescription which may influence 
medication adherence. 
5. Medication Management Plan: a living, long-term record that outlines how the 














Other than New Zealand, the pharmacist-led medication review services are also present 
in the following countries: 
1. United States of America (USA) (Medication Therapy Management) [214,215] 
2. United Kingdom (UK) (Medicines Use Review, MUR) [216] 
3. Canada (MedsCheck) [217] 
4. Australia (Home Medication Review, HMR) [218,219,220]  
 
A detailed account of the above-mentioned medication review services is available in 
“Appendix A” at the end of this thesis. 
Optimization of medication based on the risk-benefit ratio and patient education to 
improve medication adherence are the core elements of the medication review services 
[214,215,216,217,218,219,220]. Medication use review interventions can help to 
minimize medicine wastage and enhanced cost effectiveness by promoting appropriate 
use [217]. Patient education and/or counseling can increase medication adherence in 
patients with low health literacy [214,215,218,219,220]. On the basis of medication 
review, a pharmacist can recommend the physician about any possible or existing drug-












1.5 Overview of the research conducted in this thesis 
The desired therapeutic outcomes can be achieved with medication adherence 
[56,65,148,168] and poor health outcomes can be linked to medication non-adherence 
[150,159,221]. Despite being debated and discussed over the last five decades, 
medication non-adherence is still a major issue, which must be treated as a prime 
healthcare affair and there should be a policy for developing a standard strategy to 
improve it [58,59]. To our knowledge, there is scarce literature on the implementation 
and outcomes of an adherence support service when provided as “routine” or real-world 
care. Therefore, the research for this thesis began with retrospectively examining MUR 
records of the consultations provided in a single locality in New Zealand.   
New Zealand is separated into 20 DHBs, which divide the country into 20 non-
overlapping geographical areas, and each DHB has a degree of autonomy in health 
services provided.  This study was set within Bay of Plenty DHB, that covers an area of 12 
231 km2. A total of 340 283 patient records were accessed.   
This region was chosen because: 
- It was one of the few DHBs where MUR services were established from the very 
beginning of the Government announcement  
- The MUR service was fully Government funded within this DHB 
- The area has mixed population with diverse ethnicity and socioeconomic status  
- The area has higher Māori (indigenous) population 
- The research team has had previous collaboration with this DHB which facilitated 
the data collection 
The study aimed to determine if adherence support services were provided as part of 
routine practice influence adherence and clinical outcomes. However, it was unknown 





how many other patients would benefit from access to this service, and specifically what 
the adherence level is within the local population. 
Within New Zealand (NZ) each patient has a unique health identifier or National Health 
Index (NHI number).  All medicine dispensed for that patient under the government 
supply schedule are held in a central database, maintained by the Ministry of Health 
(MoH). The next study aimed to use centrally held dispensing data (Pharmhouse) to 
determine the utilization of oral hypoglycemic (OHG) medications, in the study region as 
a surrogate marker for Type 2 diabetes mellitus patients.  The research also aimed to 
determine medication adherence using surrogate markers including the proportion of 
days covered (PDC) and medication possession ratio (MPR) derived from pharmacy 
dispensing records.   
Diverse chronic diseases are inevitable in the aging human body with compromised 
organ functions and such conditions warrant a complex drug regime for overall well-
being [222,223]. Hence, polypharmacy related medication non-adherence in the older 
population is well documented in clinical research settings 
[224,221,225,226,227,228,229,230]. Beyond the older adults and at all levels of the 
population, non-adherence is a problem in public health [56,65]. One of the studies aimed 
to evaluate the drug burden and co-dispensing in patients taking OHG and further to 
determine the influence of polypharmacy on medication adherence. 
Another study aimed to determine the feasibility of compiling routinely-collected health 
information for the long-term evaluation of MUR service.  Specifically, Pharmhouse data 
and hospitalization information held were collected (where available) for the previously 
identified patients from the first study that received this service. It also aimed to identify 
a correlation between the adherence scores given by the pharmacist in the MUR 





consultation and proportion of days covered (PDC), estimated from dispensing data.  In 
this process, the scoring system used by the pharmacist during these consultations will 
either be validated or not. This will also allow the feasibility, to be determined, and in 
addition, will generate data that will allow prediction of numbers needed in future power 
calculations. The main objectives of this research project were to: 
1. investigate if medication adherence scores were improved with follow-up MUR 
visits and whether the adherence at MUR consultations was correlated to changes 
in clinical biomarkers (e.g. HbA1c level or lipid level) 
2. determine the feasibility of collecting and collating clinical information that has 
been routinely collected for a cohort of patients that received MUR  
3. determine the frequencies of hospital admissions in this cohort to allow future 
power calculations to be made. 
4. use the Pharmhouse dataset to determine the proportion of days covered i.e. PDC 
(surrogate adherence indicator) and to compare this adherence measure with the 
measure given by the pharmacist at the MUR consultation. 
5. retrospectively examine the Pharmhouse records of a large regional population 
(real world data) to determine the numbers and frequency of patients receiving 
oral hypoglycemic medications (OHG) and further to determine the level of drug 
burden and co-dispensing in those patients within a single New Zealand locality. 
6. calculate the proportion of days covered (PDC) and medication possession ratio 
(MPR) to determine the level of medication adherence in a large population (real 
world)   
7. determine the influence of the type of therapy, daily dose, drug shift or treatment 
intensification, polypharmacy on the medication adherence measurement.  





1.5.1 Characteristics of the datasets used to conduct the research  
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1.6 Overview of thesis chapters 
To address the key research objectives stated above, the project was divided into four 
phases. The findings from each phase are outlined in chapters 1 to 4 of this thesis. 
Chapter two: The influence of pharmacist-led adherence support on medication 
adherence and clinical biomarkers.  
Chapter three: A feasibility study to determine if routinely collected data can be used to 
determine the clinical outcomes of Medication Use Reviews (MUR).  
Chapter four: Using pharmaceutical collection data to determine the prevalence of oral 
hypoglycaemics use, co-dispensing, and drug burden.  
Chapter five: Proportion of days covered (PDC) as adherence measure & factors affecting 
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The influence of pharmacist-led adherence support on 








Part of the research presented in this chapter has already been published in IJCP 2018: 
Kharjul M, Braund R, Green J. The influence of pharmacist-led adherence support on 







A novelty statement 
Providing individualized adherence support to patients is anticipated to enhance clinical 
outcomes for patients.  However, there have been limited studies in real-world settings 
to measure this.  This study used the data collected in a natural setting to determine the 
influence of follow-up support service visits on medication adherence scores and to 
determine whether adherence support can positively influence HbA1c levels or lipid 
profile. The estimate of adherence in a Pharmacist-led adherence support service was 
related to change in HbA1c and lipid levels, meaning that people identified with poor 
adherence profile would benefit from further adherence support. An additional finding 
was that there was inadequate monitoring of HbA1c levels within this population.






Improving adherence to appropriately prescribed medications enhances clinical 
outcomes [56,231]. For this reason, many countries have implemented adherence 
support programmes to provide tailored, individualized strategies to help patients 
improve adherence to medications [232]. Pharmacists have been at the centre of these 
programmes and work either with patients alone or as part of a wider healthcare team, 
particularly liaising with general practitioners [233]. 
One widely implemented class of strategy involving pharmacists comprises a structured 
interview with a person to identify current adherence and individualized solutions to 
improve adherence. These pharmacist-led medication review programmes have different 
names depending on the country, however, the general format remains consistent. 
Examples include Medication Therapy Management (MTM, United States of America), 
MedsCheck (Canada), Medicines Use Review, (MUR, United Kingdom) and Home 
Medication Review (HMR, Australia) [217,218,234,235]. These interventions can be 
conducted in various settings (i.e. patient homes, community pharmacy and via 
telephone). 
Within New Zealand (NZ), this service is called a Medication Use Review and Adherence 
Support Service (MUR). In 2007, the New Zealand Government highlighted the Optimal 
Use of Medicines as one of the key outcomes of The Medicines New Zealand Strategy 
[208]. The Strategy noted that “Optimal use activities are crucial to ensuring that medicines 
that are assessed as being high-quality, safe and effective, are chosen, delivered and used in 
a way that ensures their potential to improve health and prevent illness is maximized. 
Optimal use activities also reduce wastage, enabling resources to be used effectively” [208]. 
It aims to improve patient’s understanding of and adherence to medicines; identifying 





and addressing factors linked to non-adherence behaviours, as well as minimizing 
pharmaceutical waste [208].  This service is funded in some District Health Boards 
(DHBs). The eligible patients are those living independently in the community with 
chronic disease/s or one or more of given conditions including, having multiple 
prescribers, polypharmacy, recent hospitalization, medicines with low therapeutic index, 
and impaired sight or cognitive deficiencies affecting medicine management [208].  
MUR is targeted at patients with difficulties in understanding and adhering to 
medications, and they receive personalized education and support to improve self-
management. This is achieved through tailored education to patients about the 
understanding of their prescribed medications and an agreed action plan to address 
adherence issues. The main activities covered in MUR services are medicines 
information, medicines reconciliation (based on the reported allergies and adverse drug 
reactions and comparing this with the prescribed medicines), synchronization (by 
coordinating with prescribers to assist a regular supply of medicines and accommodation 
of regimen changes), reminders to patients, evaluating medication adherence, and 
medication management plan [208].  
MUR services can be provided in a community pharmacy, hospital pharmacy, primary 
health centre, private consultant practitioners, and other settings like patient’s home, 
marae or ‘clinics’.  An accredited MUR pharmacist is trained and formally assessed against 
the Medicines Use Review Standards provided by the Pharmacy Council of New Zealand 
along with training in behavioural change management [208]. These skilled MUR 
pharmacists meet with patients face-to-face initially and determine a medication 
adherence “score” based on the framework adopted by the DHB funders. Tailored 
adherence interventions are determined and health literacy regarding medications and 





medical conditions is enhanced through dialogue. Follow-up visits are important to 
assess the person’s health outcome post-MUR and tracking changes as compared to pre-
MUR. It is also an opportunity to re-assess the person’s knowledge and understanding of 
their medicines as well as modifying strategies trialed [236]. 
Table 2.1: Scoring system of patients’ medication knowledge, adherence, and 
perceptions [237]. 
Type of score Question asked Score details 












Perception How well do you think this 
medication is working? 





MUR pharmacists rate the patient response on a scale of 1-4 (Table 2.1) to document the 
patients’ knowledge, adherence behaviour and perceptions of medications (for example 
a ‘1’ for adherence represented always missing the dose of the medications) (Appendix 
B). This scoring system was developed by the service’s funders and was implemented by 
the MUR providers [237]. The use and implementation of this scoring system were not 
influenced by this study.   





There have been several studies that have investigated the perceptions of those receiving 
these services and the wider health care team [238].  A previously published meta-
analysis of pharmacist-led fee-for-services medication reviews showed positive benefits 
in clinical outcomes including blood pressure and lipid levels [237]. It is often difficult to 
determine the direct benefits of adherence interventions in clinical outcomes as there can 
be a long period of time before therapeutic benefits are realized. Additionally, the benefits 
may be proportional to the degree of initial non-adherence and so gains may be at an 
individual level and harder to determine at a population level [239].  However, it may be 
possible to use a surrogate marker for improved outcomes, such a clinical biomarker, to 
determine whether improved adherence will have an improved clinical outcome.   
Type 2 diabetes mellitus is a condition of growing international concern.  The mainstay 
therapy for people with Type 2 diabetes mellitus is oral hypoglycemic medications.  
However, people often have suboptimal adherence to these medications. One study 
conducted in the US found that within 12 months of treatment initiation, 37% of people 
with Type 2 diabetes mellitus discontinued using their oral hypoglycemic agents [240]. 
In Europe, the CODE-2 study revealed that good glycemic control was seen with only 28% 
of people with diabetes treated with hypoglycemic agents [241]. This lack of adherence 
to oral hypoglycemic medications has led to an estimated 1 billion US dollar rise in 
medical expenses due to poor glycemic control [242,243]. One study estimated that each 
10% increase in treatment adherence could reduce the total annual diabetes care cost by 
8.6% to 28.9% [244]. 
HbA1c is a principal biomarker for glycemic control in diabetes and can be used to 
monitor the management and glycemic control of Type 2 diabetes mellitus over time.  
HbA1c levels elevated by 1% (11 mmol/mol) may trigger a 10 to 20 % rise in the 





magnitude of cardiovascular risk in people with diabetes [245].  The United Kingdom 
Prospective Diabetes Study has established that decreasing HbA1c is associated with 
decreased cardiovascular complications and lower mortality rates over time [246,247]. 
Changes in HbA1c measurement can be used to determine the impact of adherence 
interventions in the people with Type 2 diabetes mellitus as blood HbA1c levels reflect 
mean glycemic control of the preceding 2 to 3 months [248]. The New Zealand Society for 
the Study of Diabetes not only recommends the use of HbA1c for the diagnosis of Type 2 
diabetes mellitus but also suggests 3-monthly follow up HbA1c testing to avoid/manage 
complications of diabetes [249]. HbA1c testing is recommended every three months in 
people with diabetes and twice yearly for people responding positively to the oral 
hypoglycemic medication [250]. HbA1c targets differ for the diagnosis and treatment of 
diabetes. During diagnostic screening HbA1c above 50 mmol/mol confirms diabetes 
whereas for the treatment of confirmed diabetes the HbA1c in the range of 50-54 
mmol/mol reflects very good glycemic control, 55-64 mmol/mol is acceptable and above 
65 mmol/mol falls into suboptimal control demanding for intensive therapy [251].   
Among the list of different chronic disorders, hyperlipidemia is an important condition 
where blood lipid levels (as a clinical biomarker) can be measured for evaluating the 
therapeutic outcomes of anti-hyprlipidaemics.  
Elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides signify 
hyperlipidemia and may trigger the risk of stroke and myocardial infarction [252]. The 
risk of atherosclerotic cardiovascular disease (ASCVD) is high due to plaque build-ups as 
a result of rising LDL-C concentration in the blood. HDL-C also known as “good 
cholesterol” helps to clear cholesterol, hence improved HDL-C levels may restrict the 
cardiovascular risk [253].  





New Zealand health guidelines for acceptable blood cholesterol levels are [254]: 
 Total cholesterol – less than 4.0 mmol/L 
 Triglycerides – less than 1.7 mmol/L 
 LDL cholesterol – less than 2.0 mmol/L 
 HDL cholesterol – greater than 1.0 mmol/L 
 TC/HDL ratio – less than 4.0 
The total cholesterol (TC) result indicates the total amount of all the different kinds of 
cholesterol in the bloodstream. The TC/HDL ratio is used to calculate the risk of heart 
attack or stroke. 
Medication non-adherence in lipid management deteriorates cardiovascular health and 
demands advanced healthcare facilities (e.g. hospitalization) leading to higher treatment 
costs [255,256].   
Some published clinical studies have supported the impact of pharmacist-led 
interventions on medication adherence [257,258] and subsequent improvement in 
clinical biomarkers [259,260,261]. However, again these were conducted under trial 
conditions. To our knowledge, there is scarce literature on the implementation and 
outcomes of an adherence support service when provided as “routine” or real-world care. 
Therefore, the aim of this study is to retrospectively examine MUR records of the 
consultations provided in a single locality in New Zealand to determine if adherence 
support services provided as part of routine practice influence adherence and clinical 
outcomes, specifically HbA1c or lipid levels. 






2.2.1 General aim 
The aim of this study was to retrospectively examine the MUR records of a patient 
receiving MURs as part of routine care to determine if the MUR consultations resulted in 
a change in adherence scores and further to determine the association between 
adherence scores and HbA1c or lipid profile 
The aim was to develop a model to analyse correlation of the MUR score and clinical 
biomarkers. Once it was successfully tested in T2DM cases then to be applied for another 
chronic condition (e.g. hyperlipidaemia) 
2.2.2 Hypothesis  
Patients should show improvement in the MUR score with every follow-up visit and if 
there is a good MUR score in the beginning then that should be maintained through follow 
up visits. Such a rise in the MUR score with every follow up visit is a positive outcome of 
the adherence support system and subsequently may improve the treatment outcomes. 
As higher MUR score represents good adherence, the patients with a higher MUR score 
would potentially have lower mean HbA1c (or low cholesterol) and patients with lower 
MUR score would potentially exhibit elevated HbA1c levels (or higher cholesterol) over 
the time period. The adherence support system (MUR) score can be correlated to actually 










a) To investigate if adherence scores were improved with follow up MUR visits and 
whether the existing higher adherence score of the first visit was sustained over 
follow up MUR visits. 
b) To investigate if adherence at MUR consultations were correlated to changes in 
HbA1c and to determine whether the people received appropriately timed lab 
tests (HbA1c) as per guideline recommendations. 


















2.4 Participants and methods 
2.4.1 Study design (retrospective study) 
New Zealand is divided into 20 District Health Boards (DHBs), and while many core 
health services are funded at a national level, some services such as a pharmacist-led 
Medicines Use Review and Adherence Support Service (MUR) are funded only within 
specific DHBs. This study was conducted in one specific DHB that had a population of 
267,741 patients (2013 census) and funded the MUR service. As part of the MUR service, 
all consultations are documented and patients sign a consent form to receive this service 
and for their records to be used in research to inform the evaluation of the service. 
2.4.2 Data collection 
Following ethical approval (NXT/11/EXP/182), the pharmacies that provide this service 
were invited to participate in this study and those that chose to participate allowed the 
researchers access to all of the consultation files from 1 November 2007 to 31 Dec 2011. 
A total of 350 records were obtained from the MUR providers.  Subsequent data 
extraction included demographic details: age, gender, ethnicity, MUR visits, and 
medication prescribed. Adherence scores were also extracted from the records, 
measured on the scale of 1-4 (Question asked - How often do you miss a dose of this 
medication? 1– Always, 2 – Often, 3 – Seldom and 4 – Never). MUR providers have 
adopted this scoring system which was originally developed by the service’s funders.  
The pathological records for these 350 patients were separately obtained. Pathological 
data provided information about clinical biomarkers like HbA1c, lipid levels, and patient 
demographic details. Pathological and MUR records were linked with patient ID and then 
replaced with a study number.  The patients’ information was irreversibly de-identified 





and the results were only linked to a generated code. Therefore, the data won’t be able to 
link back to an individual patient.  
The MUR and pathology data were merged to allow longitudinal tracking of the 
individuals.  The first MUR visit date was considered as reference and the final analysis 
was done for a time period of ± 52 weeks from first MUR. As MUR services are provided 
to the people with chronic conditions, each patient’s records were scrutinized to 
determine whether that had sufficient documentation to determine that they had T2DM 
and that they had complete data for analysis.  This process is shown in Figure 2.4.2 as 
(b) pathway and indicated that 88 people had T2DM, of which 86 people were included 
in the final analysis. 180 out of 350 people had anti-hyperlipidemia medication (Figure 
2.4.2 pathway (c)) of which 155 people were included in the final analysis (± 52 weeks 
from first MUR). 
 
Figure 2.4.2: Flowchart of patient records qualifying for final statistical analysis with 
different objectives (a, b & c).  
 






For Study 1(a) 
The first MUR visit date was considered as a reference and follow up visit adherence 
scores were compared with that of the first one. 
For Study 1(b) 
Generalized estimating equations (GEEs) were used to explore the change in HbA1c over 
time, and whether this was related to the adherence score given by the pharmacist in the 
first MUR (88/350 records). GEEs are a generalized linear model (similar to ANOVA and 
mixed models) but are particularly robust in situations where the number of 
measurements per participant, and the timing of these measurements, are not standard 
[262], in this case, the timing of the HbA1c measurements. HbA1c was the dependent 
variable, with observations nested within persons (which served as a random factor). 
Adherence was scored so that 4 (complete adherence) was the reference level, with 
contrasts for 3, as well as 2 and 1 combined (there were only two people estimated as 
having level 1 adherence). Adherence was a fixed factor, and the time of the HbA1c testing 
was included as a continuous covariate. An autoregressive (AR1) covariance structure 
was used to model the relationship between successive HbA1c scores within each person. 
To determine the pattern of HbA1c testing frequency and the adherence to the testing 
guidelines, the number of HbA1c tests for a person was calculated for each year.  These 
were then grouped according to whether they matched the guidelines every year of 
testing (i.e. tested every 3 months), where none of the years had sufficient testing, or 
“mixed” where some years adequate testing was done. 





For Study 1(c) 
Generalized estimating equations (GEEs) were used to explore the change in lipids over 
time, and whether this was related to the adherence score given by the pharmacist in the 
first MUR. GEEs are a generalized linear model (similar to ANOVA and mixed models) but 
are particularly robust in situations where the number of measurements per participant, 
and the timing of these measurements, are not standard [262], in this case, the timing of 
the lipid level measurements. Lipid levels were the dependent variable, with 
observations nested within persons (which served as a random factor). Adherence was 
scored so that 4 (complete adherence) was the reference level, with contrasts for 3, as 
well as 2 and 1 combined (there were only two people estimated as having level 1 
adherence). Adherence was a fixed factor, and the time of the lipid testing was included 
as a continuous covariate. An autoregressive (AR1) covariance structure was used to 
model the relationship between successive lipid scores within each person. 
 
2.4.3 Data analysis 
Inferential statistical tests were conducted using software IBM SPSS Statistics version 23. 















2.5. Results  
2.5.1 Results for Study 1(a) 
 
Figure 2.5.1: Flowchart of patients analyzed for follow up MUR visits.   
Out of 316 valid MUR visit records, 201 patients had a single documented visit and only 
115 patients had followed up MUR visits as shown in Figure 2.5.1. Poor adherence (n=47, 
23.4%) was significant in the patient’s missing follow up MUR visit. The majority of the 
patients had only two follow up MUR visits (n=75, 65.2%) very few had four or more 
follow up visits (n=14, 12.2%). 
 
Table 2.5.1.1: Influence of follow up visits on the first MUR visit adherence. 
First visit vs follow up adherence Sustained Improved Reduced Total 
Non adherence (MUR score 1) 1 2 0 3 
Poor adherence (MUR score 2) 10 25 0 35 
Good adherence (MUR score 3) 38 9 3 50 
Complete adherence (MUR score 4) 25 0 2 27 
Total 74 36 5 115 
 





The changes in MUR adherence scores as compared to the first MUR visit are summarized 
in Table 2.5.1.1. Patients with MUR scores 1 & 2 collectively (n=27, 71.1%) showed 
improvement in follow up MUR visit scores when compared with their first visit score. 
Patients with MUR scores 3 & 4 collectively (n=63, 81.8%) sustained their first visit score 
over follow up visits and 9 (18%) patients with MUR score 3 improved to MUR score 4. 
Despite being highly adherent, 5 (6.5%) patients had a documented fall in their MUR 
scores with follow up visits.  
 
Table 2.5.1.2: Demographics of 115 patients with valid follow up MUR visits. 
Gender / Ethnicity Male Female Total 
Māori 25 27 52 
European 25 38 63 
Total 50 65 115 
 
Gender / Age group Male Female Total 
35 - 44 2 0 2 
45 - 54 1 2 3 
55 - 64 12 11 23 
65 - 74 20 19 39 
75 - 84 12 21 33 
85 - 94 3 10 13 
95+ 0 1 1 
Total 50 64 114* 
*Gender/age group information was missing for one patient 
A follow-up visit was higher in female patients and older patients aged between 55 to 84 
years (Table 2.5.1.2).  
 





2.5.2 Results for Study 1(b) 
The demographics of the 88 people with T2DM who had valid HbA1c, valid adherence 
score and prescribed oral hypoglycemic medication(s), are shown in Table 2.5.2. Only 
86 people had valid observations available for the duration of ± 52 weeks from their first 
MUR consultation. 
 
Table 2.5.2: Demographics of 88 people with T2DM  
Gender / Ethnicity Male Female Total 
Māori 21 25 46 
European 17 25 42 
Total 38 50 88 
 
Gender / Age group Male Female Total 
35 – 44 1 0 1 
45 – 54 0 1 1 
55 – 64 2 4 6 
65 – 74 10 14 24 
75 – 84 15 15 30 
85 – 94 7 12 19 
95+ 3 3 6 
Total 38 49 87* 
*Gender/age group information was missing for one patient 
The people with the lowest MUR adherence score (1 & 2 combined) had average HbA1c 
levels over ~ 1% (11 mmol/mol) higher than those with MUR score 4 (the reference 
category), B =10.5, p = 0.014, but there was no difference between people with MUR score 
3 & MUR score 4, B = 0.7, p = 0.8. There was a marginal trend for a slight decrease with 
time of HbA1c levels, B = -0.04, p = 0.08, but this was qualified by an interaction between 
adherence level and time. Specifically, as shown in Figure 2.5.2, the people with lowest 





MUR adherence scores (1 & 2 combined) had HbA1c scores that increased by ~ 0.1% (1 
mmol/mol) every 10 weeks, B= 0.11, p = 0.009. In contrast, people with MUR score 3 and 
MUR score 4 trends down over time, but those with MUR score (1 & 2) start high and 
continue trending up with time.  
Laboratory data were obtained separately for these 88 patients. 41 of these patients did 
not receive adequate monitoring (HbA1c measured every 12 weeks), 40 of these patients 
had mixed monitoring where some years had adequate monitoring and other years had 
reduced monitoring, and only seven patients received the level of monitoring 
recommended in the guidelines. During the course of this study, we found that 27 patients 
of the original 350 (Figure 2.5.1) had elevated HbA1c levels in their pathology data, but 
no oral hypoglycaemic agent prescribed during the period in which data were available. 
 
 
Figure 2.5.2: Changes in HbA1c over time by patient adherence levels. 
 





2.5.3 Results for Study 1(c): 
The demographics of the 180 people with valid lipid levels, valid adherence score and 
prescribed anti-hyperlipidaemia oral medication(s), are shown in Table 2.5.3. Only 155 
people had observations available for the duration of ± 52 weeks from their first MUR 
consultation. 
 
Table 2.5.3: Demographics of 180 people with anti-hyperlipidaemic medication.  
Gender / Ethnicity Male Female Total 
Māori 42 42 84 
European 45 51 96 
Total 87 93 180 
 
Gender / Age group Male Female Total 
25-34 1 0 1 
35 - 44 2 1 3 
45 - 54 4 5 9 
55 - 64 18 17 35 
65 - 74 35 31 66 
75 - 84 14 21 35 
85 - 94 7 10 17 
95+ 5 5 10 
Total 86 90 176* 










2.5.3.1 Total Cholesterol (TC): (should be less than 4.0 mmol/L) 
 
Figure 2.5.3.1: Changes in TC levels over time by patient adherence levels. 
 
The people with the lowest MUR adherence score (1 & 2 combined) had average TC levels 
over approx. 1 mmol/L higher than those with MUR score 4 (the reference category), B 
=0.9, p < 0.001, but there was no difference between people with MUR score 3 & MUR 
score 4, B = 0.3, p = 0.049. There was a marginal trend for a slight decrease with time of 
TC levels, B = -0.001, p = 0.145, but this was qualified by an interaction between 
adherence level and time. Specifically, as shown in Figure 2.5.3.1, the people with lowest 
MUR adherence scores (1 & 2 combined) start with high TC levels and trend down with 
low margins over the time. In contrast, people with MUR score 3 and MUR score 4 start 
low (and close to normal TC levels) and trend down over time. 





2.5.3.2 Triglyceride (TG): (should be less than 1.7 mmol/L) 
 
 
Figure 2.5.3.2: Changes in TG levels over time by patient adherence levels. 
 
The people with the lowest MUR adherence score (1 & 2 combined) had average TG levels 
over 0.6 mmol/L higher than those with MUR score 4 (the reference category), B =0.601, 
p = 0.004, but there was no difference between people with MUR score 3 & MUR score 4, 
B = 0.196, p = 0.174. There was a marginal trend for a slight decrease with time of TG 
levels, B = -0.001, p = 0.214, but this was qualified by an interaction between adherence 
level and time. Specifically, as shown in Figure 2.5.3.2, the people with lowest MUR 
adherence scores (1 & 2 combined) had TG levels that increased by approx. 0.6 mmol/L 
every 10 weeks, B = -0.001, p = 0.379. People with MUR score 3 and MUR score 4 were 
close to normal and further trend down over time, but those with MUR score (1 & 2) start 
high and stay high.  
 





2.5.3.3 Low-density lipoprotein (LDL): (should be less than 2.0 mmol/L) 
 
 
Figure 2.5.3.3: Changes in LDL levels over time by patient adherence levels. 
 
The people with the lowest MUR adherence score (1 & 2 combined) had average LDL 
levels over 0.7 mmol/L higher than those with MUR score 4 (the reference category), B 
=0.734, p < 0.001, but there was no difference between people with MUR score 3 & MUR 
score 4, B = 0.260, p = 0.041. There was a marginal trend for a slight decrease with time 
of LDL levels, B = -0.001, p = 0.110, but this was qualified by an interaction between 
adherence level and time. Specifically, as shown in Figure 2.5.3.3, the people with lowest 
MUR adherence scores (1 & 2 combined) start with high LDL level and trend down with 
low margins over the time. People with MUR score 3 and MUR score 4 were near to 
normal levels and further trend down over time.  
 





2.5.3.4 High-density lipoprotein (HDL): (should be more than 1.0 mmol/L) 
 
 
Figure 2.5.3.4: Changes in HDL levels over time by patient adherence levels. 
 
The people with the lowest MUR adherence score (1 & 2 combined) had average HDL 
levels over 0.05 mmol/L lower than those with MUR score 4 (the reference category), B 
= -0.047, p = 0.522 but there was no statistically significant difference. There was a 
difference between people with MUR score 3 & MUR score 4, B = -0.041, p = 0.532 but not 
statistically significant. There was a marginal trend for a slight increase with time of HDL 
levels, B = 0.000, p = 0.305, but this was qualified by an interaction between adherence 
level and time. Specifically, as shown in Figure 2.5.3.4, the people with lowest MUR 
adherence scores (1 & 2 combined) had HDL levels that decreased by 0.05 mmol/L every 
10 weeks, B = 0.000, p = 0.489 but not statistically significant. All people had HDL levels 
within the normal range. 
 






2.5.3.5 TC/HDL ratio: (should be less than 4.0 mmol/L) 
 
 
Figure 2.5.3.5: Changes in TC/HDL ratio levels over time by patient adherence levels. 
 
The people with the lowest MUR adherence score (1 & 2 combined) had average TC/HDL 
ratio levels over approx. 1 mmol/L higher than those with MUR score 4 (the reference 
category), B =0.944, p < 0.001, but there was no difference between people with MUR 
score 3 & MUR score 4, B = 0.3336, p = 0.071. There was a marginal trend for a slight 
decrease with time of TC/HDL ratio levels, B = -0.002, p = 0.036, but this was qualified by 
an interaction between adherence level and time. Specifically, as shown in Figure 2.5.3.5, 
the people with lowest MUR adherence scores (1 & 2 combined) start with high TC/HDL 
ratio levels and trend down with low margins over the time. In contrast, people with MUR 





score 3 and MUR score 4 starts within normal levels and stay in the normal range over 
time. 





2.6. Discussion  
There were 201 (63.6%) patients with only one MUR visit (i.e. there was no follow-up 
MUR visit). Most patients without follow up MUR visits were non-adherent or poorly 
adherent. This may reflect a lack of engagement with adherence improvement.  These 
results may support the outcomes of previously published articles reporting that low 
therapeutic compliance may lead to treatment failure and increased healthcare cost 
[263,264,265,266,267]. 
Documented evidence suggests that healthcare access can be influenced by health 
literacy [268]. Patients with low health literacy may fail to understand the information 
given by clinical setups. These factors lead to ultimately delayed healthcare access [268]. 
Even many patients with good or complete adherence failing to revisit was an important 
observation. Patients with a positive attitude towards their medication should be kept 
motivated, hence follow up visit for treatment-adherent patients is essential. Most 
patients that had a low adherence score at their first MUR visit showed an improvement 
in their adherence scores after subsequent follow-up visits.  This may indicate that 
medication review service can enhance medication adherence, which is also supported 
by the findings from internationally published literature [147,149,233,257,258,267,269].  
However, given that only 115 of the original 350 patients had a follow-up visit this needs 
to be further studied; particularly, the identification of the reasons for non-follow up for 
the majority of patients.  
It is acknowledged that often non-adherence is obscured from prescribers and 
unrevealed by patients as it is a concealed problem [270].  “Adherence is a dynamic 
process that needs to be followed up” was a take-home message from the World Health 





Organisation’s critical review published in 2003 [56]. This study supports the hypothesis 
that increasing follow up MUR visits may improve medication adherence. 
An important finding of study 1(b) was that those people with high adherence (MUR 
score 3/4) had decreasing HbA1c levels which fell within the defined acceptable range 
[251]. Here acceptable range of HbA1c levels in T2DM are different than those of the 
normal healthy person [252]. Conversely, those people who had poor adherence (MUR 
score 1/2) continued to show an increase in HbA1c level with time. This indicates both 
the direct impact of increased adherence on disease progression and further the influence 
of this type of service in improving adherence and subsequently HbA1c. As discussed in 
the introduction, many countries are recognizing the importance of improving 
medication adherence and have initiated services to improve adherence. These services 
have had a very little evaluation of their impact in a real-world population. The first ever 
study in United Kingdom, determining associations between adherence and clinical 
outcomes across the oral hypoglycaemic treatment paradigm in large general cohort of 
patients with Type 2 diabetes was published in May 2018 [271]. However, it has been 
noted in other studies that targeted education to people regarding their diabetes has 
shown a direct impact in improving HbA1c [272,273,274].  One aspect of the MUR 
consultation is indeed education and so this aligns with others findings. Further, other 
studies have also indicated the importance and impact of a comprehensive care package 
for people with diabetes and that targeted care will enhance the achievement of glycemic 
targets [273,274]. 
At the time these MUR consultations were conducted the pharmacist had no access to any 
pathology data.  Recently, within New Zealand, there has been a change in the sharing of 
health information held by individuals. This has increased the access that pharmacists 





have to laboratory results for people under their care [275]. Laboratory data / medical 
records shared with pharmacists may be advantageous to improve safety and avoid 
medication errors [276,277,278,279,280]. This may allow the pharmacist to speak with 
the people directly about the importance of monitoring treatment efficacy or via the 
prescriber in a more collaborative care model.  This is important as often prescribers may 
be unaware of non-adherence and people may not feel comfortable disclosing it [270]. A 
closer working relationship between pharmacists and prescribers will have positive 
outcomes for people with diabetes and multimorbidity [281,282].  
One surprising finding was the identification of a group of people who had significantly 
elevated HbA1c levels and no treatment with oral hypoglycemic initiated during the 
period of this study. Again a multidisciplinary approach and shared records which 
include prescribing, dispensing and laboratory results may allow closer monitoring. In 
this study, very few people received testing as frequently as suggested in the guidelines.  
This is an area worthy of further investigation as to whether the prescribers are not 
requesting the tests, or whether people are not actioning the requests.  
Poor medication adherence may affect the clinical outcome of anti-hyperlipidemia 
medication which can be best evaluated by analyzing the lipid level of patients. Such 
poorly adherent patients may continue to have abnormally high blood lipids despite 
being prescribed with anti-hyperlipidaemic. This can be reflected in their lipid levels 
which will keep rising with the time. The study 1(c) clearly indicate that patients with 
low adherence status had poorer lipid profile which deteriorated with time. 
There are some limitations to this study.  As the study relied on secondary data, not 
all information was available for all people. This also means that only people that were 
offered and accepted an MUR were included in this study. The adherence score given by 





the pharmacist is a non-validated tool and provides only an “estimation” of the 
individuals’ adherence as judged by the pharmacist conducting the MUR.  This scoring 
system appears blunt as it is assigned solely from the perspective of an MUR pharmacist.  
There are different measures of adherence reported in the literature which uses primary 
data in systems such as electronic prescription service or pharmacy insurance claims 
[283]. While balancing accuracy and cost, pharmacy refill measures are more favorable 
for a large research population. Medication possession ratio (MPR) is one of the popular 
measures to indicate medication adherence. Further in this thesis, there will be a 
comparison of MUR scores and MPR for the better representation of medication 
adherence. 
As mentioned above, there needs to be further research into why the remainder of 
patients did not have follow up visits.  This study found that there was sporadic and less 
than recommended testing of HbA1c, this also is an area for further research.  It is 
important to note in this piece of work that the pharmacists conducting the MUR services 
did not have access to people’s pathology results and therefore are unaware which people 
they are working with are achieving reductions in their HbA1c levels. Further, they are 
unable to recommend treatment initiation for people with elevated laboratory results 
because they are not aware that HbA1c is elevated. 
The studies evaluating adherence improvement by the pharmacist-led services, were 
conducted under clinical trial set-up (257,258,259,260,261). However, this study has 
investigated the impact of a structured adherence service when offered in a “real life” 
setting and indicated that for those patients who had follow-up visits, adherence was 
improved.  Importantly the impact of this adherence on clinical outcomes such as HbA1c 
has been shown.  





2.7. Conclusion  
“Drugs don’t work in patients who don’t take them” is a quote from former Surgeon 
General C. Everett Koop [263]. Medication consumption attitude of the patient is a 
complex phenomenon which varies with each individual. Especially patients with chronic 
illness (or taking a large number of medicines) will always need a high level of motivation 
to stick to the medication regime. Adherence support services can play a major role in 
such patients and there is need of encouraging patients for taking sufficient follow-up 
visits to these services.     
Pharmacists performing an adherence support service can positively influence 
medication adherence.  Patients with high adherence scores showed a decline in 
measured HbA1c and lipid levels; conversely, the people who are poorly adherent, have 
an elevated HbA1c and lipid profile. 
The major limitations of the MUR adherence scoring system is its subjectivity and the 
strong potential for social desirability response bias in patients’ responses and therefore, 
current analyses are useful because they look at other data (clinical biomarkers) to assess 
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Optimal medication therapy and the patient’s adherence to this therapy are the important 
drivers to the success of medication treatment. Medication non-adherence or poor 
adherence not only threatens patient health but impacts the wider healthcare system in 
terms of increased resourcing.  For this reason, improving medication adherence is a 
major public health concern. Appropriately educating people about their medicines may 
help avoid the possible future relapse of their condition and subsequent hospitalization 
[284]. 
Poor medication adherence results in poor health outcomes and increased health care 
costs [263]. In poorly adherent patients with chronic disease, the risk of hospitalization 
is twofold or higher than the general population [284]. The rate of hospitalization has 
been seen to decrease with higher medication adherence (where adherence was 
measured by the proportion of days covered). This helps in reducing medical expenses 
as hospitalization is a costly part of the health service [256]. 
In 2007, Medicines Use Review and Adherence Support services (MUR) were introduced 
in New Zealand as part of the National Pharmacist Services Framework. The MUR service 
involves accredited community pharmacists interviewing and reviewing a patient’s 
medication for potential or actual medicine-related problems. During these 
consultations, the pharmacist specifically assesses a patient’s adherence using a numeric 
score of 1 to 4. In this system, an MUR score of 1 indicates very poor adherence or non- 
adherence and 4 indicates complete adherence [236].  
In New Zealand, at present, there has been no study conducted correlating MUR service 
impact on any future clinical outcomes including hospitalization.  





During 2012, a study was conducted within the Bay of Plenty (BoP) DHB to determine the 
types of interventions conducted by pharmacists during an MUR consultation [136].  
During that study, data were collected on 350 patients.  A further study on this group of 
patients has been conducted to determine the influence of adherence changes on 
biomarkers (i.e. lipid profile and HbA1c) as a surrogate for clinical improvements (refer 
chapter two) 
This study aims to determine the feasibility of analysing routinely collected health 
information for the long term evaluation of this type of service.  Specifically, Pharmhouse 
data and hospitalization information held will be collected (where available) for the 
previously identified 350 patients that received this service in the BoP. We anticipate that 
this study will provide information as to the feasibility of this methodology to investigate 
long-term clinical outcomes for patients receiving these types of services.  
In the short term, this study will also identify the correlation between the adherence 
scores given by the pharmacist in the MUR consultation and proportion of days covered 
(PDC) estimated from dispensing data.  In this process, the scoring system used by the 
pharmacist during these consultations either will or will not be validated. This will also 
allow the feasibility, to be determined, and in addition, will generate data that will allow 
prediction of numbers needed in future power calculations. In chapter two, it was found 
that increased medication adherence in a group of patients receiving MUR improved 
biomarkers. This chapter is to extend on this work to look at whether routinely collected 
data can be used to determine the clinical outcomes of MUR. In the previous chapter, the 
concept of PDC was introduced and used to determine adherence.  This chapter will use 
this method to objectively determine the adherence of the cohort of patients that received 
MUR. During MUR intervention, medication adherence was measured on a scale of 1-4 





(here the question asked was - how often do you miss a dose of this medication? 1– 
always, 2 – often, 3 – seldom and 4 – never). MUR providers have adopted this scoring 
system which was originally developed by the service’s funders. This will be considered 















To determine the feasibility of collating routinely collected clinical information to allow 
the long-term evaluation of pharmacist-provided adherence support services, specifically 
MUR 
3.3 Objectives 
a) To determine the feasibility of collecting and collating clinical information that has 
been routinely collected for a cohort of patients (n=350) that received MUR in the 
Bay of Plenty DHB during (2007-2012) 
b) To determine the frequencies of hospital admissions in this cohort to allow future 
power calculations to be made. 
c) Further using the Pharmhouse dataset to determine the proportion of days 
covered in the study cohort i.e. PDC (another adherence indicator) and to compare 
this adherence measure with the measure given by the pharmacist at the MUR 
consultation. 













3.4 Participants and methods 
Ethical approval was obtained from the New Zealand Health and Disability Ethics 
Committee, (17/CEN/120). 
Privacy and confidentiality 
In the Pharmhouse & MUR data, patient ID were removed and replaced with a study 
number.  Then patients’ information was irreversibly de-identified and the results were 
linked only to a generated code.  
3.4.1 Data source 
Following ethical approval (NXT/11/EXP/182), the pharmacies that provide MUR 
service were invited to participate in this study and those that chose to participate 
allowed the researchers access to all of the consultation files from 1 November 2007 to 
31 Dec 2011. A total of 350 records were obtained from the MUR providers. During the 
consultations, patients were assigned with a numeric value to indicate the adherence 
level as determined by the pharmacist.  
The unique identifier NHI was used to request from the Ministry of Health, New Zealand 
to obtain the National Minimum Dataset (NMD) records of these 350 patients for hospital 
admission/events over the period 2000-2016 (or last currently available date). A further 
request was made to obtain the Pharmhouse data for this cohort and investigate the 
dispensing records for the period 2007-2015.  This data was used to estimate the 
proportion of days covered (PDC) as an independent adherence indicator. 
As the MUR visits were between the year 2007 and 2011, the hospitalisation records were 
ordered from the year 2000 to 2016. The long spread of duration may facilitate the 
tracking of hospitalisation before and MUR visit for the reliable results. 
 






3.4.2 PDC as adherence indicator vs Pharmacist-led MUR adherence scores 
The proportion of days covered (PDC) was estimated using the Pharmhouse data 
obtained for 350 patients. The proportion of days covered in a year with CVS/OHG/CNS 
medication and calculated using the following equation [92]:  
PDC =
D × 100
365 –  1
 
Here “D” is a number of days on which the patient has the medication available (e.g. total 
days’ supply – any overlapping supply from early fills). “– 1” was for a day of last 
dispensing. A PDC ≥ 80% is a commonly accepted index of adherence 
[56,85,94,108,231,285]. PDC was used as a surrogate marker for medication adherence. 
As discussed in the introductory chapter, for the valid calculation of PDC there should be 
multiple dispensing records over a period of a few years. Hence only 280 out of 350 
patients were included for this study as the remaining patients were missing with follow-
up dispensing (Figure 3.4.2).   
 
Figure 3.4.2: Grouping of patients with valid PDC based on different medications. 
The 280 patients were grouped based on the major class of dispensed medication (Figure 
3.4.2). 





For the same 280 patients, the medication adherence scores were also available from 
Pharmacist-led MUR service reports which were provided on the scale of 1 to 4 (1 being 
non-adherent and 4 as completely adherent). We developed a virtual scale to rate PDC 
(as percentage values) as 1 to 4. These conversions and their significance are summarised 
in Table 3.4.2. 
Table 3.4.2: Developing virtual scale for matching PDC values with MUR. 






< 50 1 1 Non-adherence 
50 – 79.99 2 2 Poor adherence 
80 – 89.99 3 3 Good adherence 
≥ 90 4 4 Complete adherence 
 
Most of the published literature based on adherence science reported that PDC ≥ 80% as 
a commonly accepted index of adherence [56,85,94, 231,108,285]. Taking the cue from 
such scientific publications, the PDC based virtual scale was developed to match the 
current research. 
The PDC based virtual scale and documented MUR scores were compared for each patient 
to check whether the PDC based virtual scale can validate the documented MUR scores 
from a pharmacist intervention.    
For the cases where PDC failed to match with MUR adherence score, there was a further 
analysis to find out the under or overestimation of MUR score (as compared to PDC 
value). 
 3.4.3 Hospitalisation before and after MUR visit for patients with OHG 
As the current thesis focuses on T2DM patients, to be consistent with the thesis theme 
this study evaluated hospitalization only in T2DM patients. Also, the results from chapter 





two demonstrated that T2DM patients with high adherence scores showed a decline in 
measured HbA1c level and the current study aims to determine if that can influence the 
further clinical outcomes, i.e. hospital admissions. There were 85 OHG patients with valid 
hospitalization & MUR records. These patients were scrutinized to find out the number 
of hospital admission/s before and after MUR consultation visits. The MUR visit report 
provided information about the patient ID, gender, ethnicity, age, date of visit and the 
adherence score assigned by a pharmacist. Whereas, hospitalization records informed 
about the general demographics and date of admission and discharge. These two records 
were merged to create a single file to determine the number of hospitalization before and 
after MUR consultation date. Firstly, the total number of hospitalization before and after 
each MUR visit for every patient was counted and secondly the time frame was narrowed 
to count hospital admissions within one year from MUR visit.  
Analysis of a total number of hospitalizations 
If the number of hospital admissions was higher after the MUR visit than those before the 
visit, then it was considered an increase in hospitalization. The opposite of this was 
considered a decrease in hospitalization. No change was noted if the count of hospital 
admissions was the same before and after the MUR visit.    
Hospitalization analysis within a year time frame from MUR visit 
The criteria for increased, decreased or no change in hospitalization was the same as for 
a total number of hospitalization analysis. For the within-year analysis, there was the 
addition of a fourth case, i.e. zero admission before and after MUR visit. As zero 
hospitalization indicates a better health management effortof a patient, these efforts 
were also maintained after the MUR visit, resulting in avoiding the hospital admission at 





least for a year. Such cases are not exactly representing decreased hospitalization but can 
be considered as a kind of positive outcomes from MUR consultation. 
3.4.4 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. Statistical significance was taken to be P < 0.05. 
 





3.5. Results  
3.5.1 PDC as adherence indicator vs Pharmacist-led MUR adherence scores 
3.5.1.1 Demographics of patients taking different medications 
The demographics of those 280 patients with a valid PDC, with different medications are 
highlighted in Table 3.5.1.1. The dispensing of all (CVS, OHG & CNS) medications was 
significantly higher in female patients. The dispensing of CVS & CNS medications was 
significantly higher in NZ European whereas OHG dispensing was higher in NZ Māori.    
 
Table 3.5.1.1: Demographics of 280 patients with different medications.   






Patients with  
CNS 
(n=41) 
Count % Count % Count % 
Gender 
Female 74 51.0 50 53.2 25 61.0 
Male 71 49.0 44 46.8 16 39.0 
Ethnicity 
NZ European 94 64.8 43 45.7 30 73.2 
NZ Māori 51 35.2 51 54.3 11 26.8 
Index age range 
11 to 20 2 1.4 0 0.0 0 0.0 
21 to 30 0 0.0 1 1.1 0 0.0 
31 to 40 3 2.1 2 2.1 1 2.5 
41 to 50 1 0.7 2 2.1 3 7.5 
51 to 60 12 8.3 17 18.1 4 10.0 
61 to 70 30 20.8 29 30.9 7 17.5 
71 to 80 53 36.8 27 28.7 10 25.0 
81 to 90 38 26.4 14 14.9 13 32.5 
91 to 100 5 3.5 2 2.1 2 5.0 
 





3.5.1.2 Summary of 416 MUR visits by 280 patients 
There was a total of 416 MUR visits recorded for 280 patients as a few patients had 
multiple follow-up MUR consultations. Table 3.5.1.2 highlights the summary of MUR 
scores for these 416 visits based on different medications. Non-adherence (27.1%) and 
poor adherence (4.2%) was higher in patients taking CNS medications (Table 3.5.1.2). 
 
Table 3.5.1.2: Summary of 416 visits by 280 patients for their pharmacist designated 




CVS OHG CNS 
Count % Count % Count % 
1 Non adherent 7 3.3 2 1.3 2 4.2 
2 Poor adherent 43 20.0 31 20.3 13 27.1 
3 Good adherent 104 48.4 74 48.4 17 35.4 
4 Complete adherent 61 28.4 46 30.1 16 33.3 














3.5.1.3 Validation of MUR adherence scores by PDC based scale 
Comparison of the PDC based scale and MUR score for validation of MUR scores is given 
in Table 3.5.1.3. PDC based scale validates MUR scores in 52.9% of patients taking OHG 
medications and in 58.3% of cases taking CNS medications. For the patients failing to 
validate they were further analyzed for under/overestimation of MUR adherence score.  
 
Table 3.5.1.3: The comparison of PDC based scale and MUR score for validation of MUR 
scores. 
Is PDC validating 
MUR scores 
CVS OHG CNS 
Count % Count % Count % 
Yes 101 47.0 81 52.9 28 58.3 
No 114 53.0 72 47.1 20 41.7 
Total 215 100 153 100 48 100 
 MUR adherence 
score status 
CVS OHG CNS 
Underestimated 37 32.5 41 56.9 6 30.0 
Overestimated 77 67.5 31 43.1 14 70.0 
Total 114 100 72 100 20 100 
 
As compared to PDC, the MUR adherence score was underestimated in 32.5% of CVS 
patients, 56.9% of OHG patients and 30% of CNS patients. Overestimated MUR adherence 









3.5.1.4 Underestimated cases with low adherence score and high PDC  
The underestimated cases with low MUR adherence score and high PDC are summarized 
in Table 3.5.1.4. The pharmacist generated score demonstrated good adherence (MUR 
score = 3) but the PDC-based was complete adherence (PDC > 90%) in 75.7%, 75.6% & 
83.3% of CVS, OHG & CNS cases respectively. The pharmacist-led score demonstrated 
poor adherence (MUR score = 2) but the PDC-based was complete adherence (PDC > 
90%) in 18.9%, 17.1% & 16.7% of CVS, OHG & CNS cases respectively. 
 
Table 3.5.1.4: Summary of underestimated cases with low MUR adherence score and 
high PDC.  
Characteristics 
CVS OHG CNS 
N % N % N % 
PDC above 90% & MUR = 3 (Good Adh.)  28 75.7 31 75.6 5 83.3 
PDC above 90% & MUR = 2 (Poor Adh.)  7 18.9 7 17.1 1 16.7 
PDC above 90% & MUR = 1 (Non Adh.)  1 2.7 0 0 0 0 
PDC 80-89.99 & MUR = 2 (Poor Adh.) 0 0 1 2.4 0 0 
PDC 50-79.99 & MUR = 1 (Non Adh.) 1 2.7 2 4.9 0 0 












3.5.1.5 Overestimated cases with high adherence score and low PDC  
The overestimated cases with high MUR adherence score and low PDC are summarized 
in Table 3.5.1.5. The pharmacist-generated score demonstrated poor adherence (MUR 
score = 2) but the PDC based indicated non-adherence (PDC < 50%) in 50% of CNS cases.  
The pharmacist-led score demonstrated good adherence (MUR score = 3) but the PDC-
based indicated non-adherence (PDC < 50%) in 31.2%, & 45.2% of CVS & OHG cases 
respectively. The pharmacist-generated score demonstrated complete adherence (MUR 
score = 4) but the PDC-based was non-adherence (PDC < 50%) in 15.6%, 9.7% & 21.4% 
of CVS OHG & CNS cases respectively. 
 
Table 3.5.1.5: Summary of overestimated cases with high MUR adherence score and 
low PDC. 
Characteristics 
CVS OHG CNS 
N % N % N % 
PDC 80-89.99 & MUR = 4 (Complete Adh.)  5 6.5 0 0 0 0 
PDC 50-79.99 & MUR = 4 (Complete Adh.) 6 7.8 4 12.9 2 14.3 
PDC 50-79.99 & MUR = 2 (Poor Adh.)  13 16.9 7 22.6 0 0 
PDC less than 50% & MUR = 4 (Complete)  12 15.6 3 9.7 3 21.4 
PDC less than 50% & MUR = 3 (Good)  24 31.2 14 45.2 2 14.3 
PDC less than 50% & MUR = 2 (Poor)  17 22.1 3 9.7 7 50 










3.5.2 Hospitalisation before and after MUR visit for patients with OHG 
3.5.2.1 Summary of MUR visits by patients with OHG  
The MUR visit data revealed that few patients had minimum one visit or maximum five 
no. of visits. There were a total of 137 MUR visits recorded for 85 patients with OHG as 
few patients had multiple follow-up MUR consultations. Table 3.5.2.1 highlights the 
summary of MUR scores for these 137 visits. The percentage of non-adherence, poor 
adherence, good adherence, and complete adherence was respectively found to be 1.5%, 
19%, 47.4%, and 32.1%. 
 
Table 3.5.2.1: Summary of 137 visits  
Adherence score Adherence status Count Percentage 
1 Non-adherent 2 1.5 
2 Poor adherent 26 19.0 
3 Good adherent 65 47.4 
4 Complete adherent 44 32.1 
Total 137 100 
 
Patient’s hospitalization records were analyzed to determine the number of hospital 
admissions before and after the MUR visit date. Missing hospitalization records either 
before or after MUR visit failed to generate the comparison outcome, hence such cases 
were excluded from further analysis. There were 41 (out of 137) MUR visits excluded due 
to missing hospitalization records either before or after the MUR visit. 
The hospital admission were present weeks or months apart from MUR visit date and 
sometimes years apart. To narrow down the time frame for a reasonable comparison, this 
study analyzed hospitalizations within a year from MUR date (i.e. 365 days before and 
after MUR visit). There were 4 (out of 137) MUR visits excluded from within a year 





analysis. At the end, there were 92 (out of 137) MUR visits for the final (within a year) 
analysis. 
 
3.5.2.2 Analysis of hospitalisation in patients with OHG  
The results for total and within-a-year analysis of hospitalization before and after MUR 
visit are presented in Table 3.5.2.2. 
 
Table 3.5.2.2: Status/rate of hospitalization before and after MUR visit. 
Hospitalisation rate / 
status 
Total hosp. analysis Within a year analysis 
Count % Count % 
Decreased 13 13.5 33 35.9 
Increased 72 75.0 25 27.2 
No change 11 11.5 09 09.8 
Zero before & after NA NA 25 27.2 
Total 96 100 92 100 
 
Decreased hospitalization (35.9%) from hospitalization within a year analysis (Table 
3.5.2.2) represents a positive outcome. No change (9.8%) or Zero before and after 
(27.2%) can be considered a positive outcome. So overall in 72.9% MUR visits had a 












3.5.2.1 MUR adherence vs hospitalisation in patients with OHG  
The comparison among different adherence status based on the hospitalization status by 
within a year analysis is highlighted in Table 3.5.2.3. There were zero cases with non-
adherence (MUR score 1) and hospitalization records. The collective positive influence of 
visit with good adherence, complete adherence, and poor adherence was respectively 
found to be 74.4%, 71.4%, and 71.5%.  
 
Table 3.5.2.3: MUR adherence status vs hospitalisation rate 
Adherence  
status 
Hospitalisation rate / status 
Negative                         Positive influence  
Increased Decreased No change Zero before & after 
Count % Count % Count % Count % 
Poor adherence 
(MUR score 2) 
4 28.6 6 42.9 0 0 4 28.6 
Good adherent 
(MUR score 3) 
11 25.6 16 37.2 5 11.6 11 25.6 
Complete adherent 
(MUR score 4) 















3.6. Discussion  
3.6.1 PDC as adherence indicator vs pharmacist-generated MUR adherence 
scores 
The adherence score given by the pharmacist is a non-validated tool and provides only 
an “estimation” of the individuals’ adherence as judged by the pharmacist conducting the 
MUR.  This scoring system appears blunt as it is assigned solely from the perspective of 
an MUR pharmacist. Subjective measure i.e. patient interview by healthcare professional 
identify adherence based on patient beliefs and sometimes may generate biased 
outcomes [136]. Whereas, the patient adherence patterns can be more accurately 
obtained from objective measures [286].  
The current study reported medication adherence in 280 patients with the help of 
subjective measure (pharmacist-led MUR adherence score) and objective measure (PDC 
using dispensing data). This study also compared the results of PDC measure to validate 
the MUR adherence score given by pharmacist. 280 patients collectively had 416 MUR 
visits with varying adherence levels and only in 52.7% of MUR adherence scores matched 
with PDC based adherence scores (Table 3.5.1.3). For the visits where PDC and MUR 
adherence scores were not matching, they were further analyzed to find out the deviation 
from PDC based scores. The MUR adherence score was underestimated in 39.8% visits 
and overestimated in 60.2% visits (Table 3.5.1.3). 
In underestimated cases (Table 3.5.1.4) the lower adherence scores assigned by a 
pharmacist may reflect the best adherence nature of the patient. Here, pharmacist-led 
MUR scores can be more authentic as MUR services actually interview the patients and 
analyze their medication behaviour by evaluating the overall attitude of the patient 





towards the treatment plan. In overestimated cases (Table 3.5.1.5) the pharmacist 
should also consider the dispensing history of the patients before assigning MUR scores 
for the adherence. 
3.6.2 Hospitalisation before and after MUR visit for patients taking OHG 
Compiling data on dispensing records and hospitalization information may allow longer-
term tracking of the clinical outcomes of these services.  This feasibility study may allow 
an understanding of the ability to compile this data and to generate data that will allow 
power calculations possible. 
The records of hospital admissions vary for patients ranging from a couple of months to 
many years before and after the MUR visit date. Hence, this study may support the results 
from within-a-year analysis of hospitalization as it limits the time frame of analysis 
(Table 3.5.2.2). Hospital admissions were decreased in 35.9% cases after MUR visit. This 
observation was consistent with the other studies reporting a drop in the rate of 
hospitalization after MUR or similar interventions [287,288,289,290]. In 9.8% of cases, 
the hospitalization rate was the same before and after MUR. Zero or no hospitalization 
before and after MUR visit in 27.2 % of cases may indicate a positive outcome of MUR 
consultations on the patient. On the contrary, only 27.2% of cases had increased number 
of hospital admission after MUR. Though there was no significant correlation between 
the rate of hospitalization and MUR adherence status like poor/good/complete 
adherence (Table 3.5.2.3). Mere an MUR visit may have a positive influence on avoiding 
hospitalisation as, on an average, 71-74% of collective of all adherence type cases 
belonged to positive outcomes (Table 3.5.2.3). 
 





3.6.3 Feasibility of research methods  
As mentioned in earlier studies, MUR adherence scores are subjective and they need to 
be standardised by some other reliable source. The virtual PDC scale developed using 
pharmacy administrative data may provide insights about the patient’s medication 
adherence. Such a secondary adherence can be used to validate the MUR adherence score 
obtained during adherence support services. A PDC-based medication adherence can 
easily reflect on the history of patient’s medication collection behaviour and this 
information can be useful while delivering adherence support service.   
The information obtained from hospitalisation records may help to determine the 
influence of medication review service (e.g. MUR).  However, this method, using routinely 
collected data to determine the clinical outcomes of MUR, may not be feasible as there is 
no direct correlation found between different adherence levels and rate of 
hospitalisation.   
 
3.6.4 Limitations of the study  
The PDC-based medication adherence can be useful for the govt. subsidised medicines 
only. This study can provide the very basic comparison of a number of hospital admission 
before and after MUR consultation but the nature (reason) of hospitalization was not 
studied. The hospital admissions may be not related to diabetes (e.g. accident). Another 
limitation is that for some conditions adherence needs to be maintained for a certain 
period before clinical results. 
 
 




3.7. Conclusion  
Using routinely-collected data (hospitalisation records) may not be feasible to determine 
the clinical outcomes of MUR.  
Use of a PDC-based adherence score for validating the pharmacist-led MUR adherence 
score is feasible.  
A subjective and objective measure of adherence can be used together for better or true 










Using pharmaceutical collection data to determine the 










The high prevalence of diabetes continues to be of increasing international concern [291] 
and it needs multiple strategies to achieve glycemic control to avoid future complications 
[292]. Diabetes is a truly global epidemic from both a health outcome perspective and its 
associated healthcare costs [48,293]. High blood glucose levels are the result of low 
insulin production and/or insulin resistance leading to Type 2 diabetes mellitus (T2DM). 
Hypertension, renal insufficiency, and lipid disorders are commonly co-existing with 
T2DM [294,295]. As research into chronic diseases advances, more medications become 
available. This offers more choices for prescribers but can increase the number of 
medications used in therapeutic combinations.  This is seen in patients with T2DM, where 
maintaining appropriate glucose levels, the management of complications (including 
cardiovascular) and protecting vital organs (e.g. kidneys) is essential. Despite the 
promising clinical outcome in chronic therapy with multiple medications, poor 













The different classes of oral hypoglycemic medication (OHG) for the management of 
T2DM are summarized in Table 4.1 [296,297,298]. Biguanides, sulfonylureas, 
meglitinides, thiazolidines, alpha-glucosidase inhibitors, DPP-4 (dipeptidyl peptidase 4) 
inhibitors, bile acid sequestrants, dopamine-2 agonists and SGLT-2 (sodium/glucose 
cotransporter 2) inhibitors are the different classes of OHG.    
Table 4.1: Classification of oral hypoglycemics for managing T2DM [296,297,298]. 
 
   





Figure 4.1: Guidelines for Type 2 diabetes management in New Zealand [254]. 
The guidelines for Type 2 diabetes management in New Zealand are summarized in 
Figure 4.1 [254].   
Failure to meet glycemic targets or persistent hyperglycemia may affect different organs 
or systems in the body. Peripheral vascular disease, neuropathy, retinopathy, immune 
suppression, end-stage renal disease, hypertension, erectile dysfunction, and electrolyte 
imbalance are the outcomes of diabetic complications [299,300]. These multiple and 
complex pathophysiologic defects may demand multiple target therapy (involving 
different organs) to restrict diabetic complications [296]. Regular assessment and 




necessary modification is warranted in T2DM treatment for better glycemic control and 
to decline or avoid diabetic complications [301,302].   
Worldwide, 25%-50% of patients are not taking their prescribed medications [56,303]. 
The presence of poorly controlled hyperglycemia despite the different available 
treatment options may reflect clinical inertia [304]. Glycemic targets can be achieved with 
medication adherence [305,306] and healthcare cost and healthcare resource utilization 
in T2DM are directly linked with medication adherence [307]. Non-adherence to OHG 
may be due to one or many of following reasons: multiple daily doses, adverse effects (e.g. 
hypoglycemia), flexibility and mode of administration, failure to understand 
formulations, unable to read product labels (e.g. impaired vision), and cost of treatment 
[308].  
It has been shown that 289 billion US dollars of healthcare expenditure, coupled with an 
annual rise of hospital admissions by 10% was linked with medication non-adherence in 
the USA alone [263,309,310]. Whereas, such expenditures in Australia costs 7 billion 
Australian dollars [311,312] and 1.25 billion Euro in Europe [313].  
Non-adherence is a preventable public health burden if identified, and corrected early 
[148]. As seen in the previous chapter, pharmacist-led medication adherence support 
services can be of use.  What is not clear is how large the problem of non-adherence is.  
There are many tools available to estimate medication adherence and one of them is to 
use the secondary database from the public health sector (e.g. pharmacy dispensing 
records or claims data).  This will form the methodological basis of this chapter.  
 
 




4.1.1 The significance of Health Care Administrative Data in Medication Adherence 
Analysis 
To conduct an evaluation of population behaviours, there is a need of representative and 
large samples to deliver generalizable and valid findings from epidemiologic 
observational research studies [314,315].  
Administrative databases can fulfil these data requirements as they are the archives of 
healthcare data obtained at a variety of occasions [314]. Following listed incidents or 
contacts with the healthcare system produces such datasets [316]:  
1. Receipt of a prescription at a community pharmacy 
2. Visit a physician’s office 
3. An admission to hospital 
4. A diagnostic procedure 
Health care administrative data can also be referred to “claims data” or “administrative 
claims data”, “administrative healthcare billing records” or “healthcare utilization data” 
[316]. The timely and systematic collection, wide coverage and large numbers are the 
main advantages qualifying these databases as a principal choice for epidemiological 
studies regarding [316,317,318]: 
1. The incidence of major diagnosis or diseases 
2. Drug utilization 
3. Drug safety and effectiveness 
4. Understanding the professional community pharmacy services 
A better understanding of pharmacotherapy and pharmacy practice can also be 
highlighted with healthcare administrative data [316,317]. 




There are some limitations to the use of administrative databases including [318]: 
1. Difficulties in linkage and merging of different databases 
2. Different coding criteria across individuals and institutions 
3. Lack of accuracy 
4. Changing in the coding system over time 
5. Changing criteria over time 
Within New Zealand (NZ) each patient has a unique health identifier or National Health 
Index (NHI number).  All medicine dispensed for that patient under the government 
supply schedule is held in a central database, maintained by the Ministry of Health (MoH). 
New Zealand is separated into 20 DHBs, which divide the country into 20 non-
overlapping geographical areas, and each DHB has a degree of autonomy in health 
services provided.  This study was set within a single DHB, that covers an area of 12,231 
km2. A total of 340,283 patient records were accessed.  This region was chosen as it was 
one of the few DHBs providing Medicines Use Review (MUR) adherence support services 
to patients, as detailed in the previous chapter. 
 
 





The aim of this study was to use centrally held dispensing data (Pharmhouse) to 
determine the utilization of oral hypoglycemic (OHG) medications, in the study region as 
a surrogate marker for Type 2 diabetes mellitus patients.  Further, this data will form the 
basis to evaluate the drug burden and types and no. of drugs co-dispensing in patients 
taking OHG within a single New Zealand locality. 
4.3 Objectives 
To retrospectively examine the Pharmhouse records to determine the numbers and 
frequency of patients receiving oral hypoglycemic medications and further to determine 
the level of drug burden and co-dispensing in those patients within a single New Zealand 
locality. 
4.4 Participants and methods 
The protocol review and approval was conducted and data was provided following the 
protocol request and assessment by Pharmaceutical Collections, Ministry of Health, New 
Zealand. As per the Health and Disability Ethics Committees (HDEC) guideline, a study 
does not need HDEC approval to use health information for research if “the health 
information won’t be disclosed* to researchers in a form that would allow them to identify 
the individual(s) concerned, or to match the information with other datasets through a non-
encrypted identifier (e.g. an NHI number)”. Hence there was no need for HDEC approval. 
Privacy and confidentiality 
In the data obtained for the purposes of this study the patients’ information was 
irreversibly de-identified and alternate patient ID was provided (there was no mention 
of national health index (NHI) number).  This occurs before the information data was sent 




to the research team. Therefore, the data will not be able to be linked back to an individual 
patient.  
4.4.1 Data source 
This was a retrospective observational study. The request was made to the Ministry of 
Health, New Zealand for the dispensing records of any patient that had received an oral 
hypoglycemic medication from selected DHB. The e-dispensing (Pharmhouse) records 
for selected DHB were then obtained for the period of 8 years (1st Jan 2008 to 31st Dec 
2015). This data provides information including patient ID, age, gender, ethnicity, date of 
dispensing, quantity prescribed/dispensed, daily dose, the total number of days’ supply, 
chemical & therapeutic ID of the drug (Figure 4.4.1 or Appendix C).  
 








4.4.2 Data processing 
4.4.2.1 Data compilation 
Given that this study was over a defined period, the actual date of therapy initiation for 
each patient was unknown when it was before the 1st of Jan 2008.  For consistency of 
analysis, this study considered the first recorded dispensing of OHG as index dispensing. 
Not all the patients had their index dispensing on 1st January of every calendar year. Some 
patients had their index dispensing in the middle of the year and last dispensing 
extending over the period of few years or few months. To ensure that all analysis was 
consistent, the Pharmhouse records were combined (Figure 4.4.2.1) from 2008 to 2015 
and days between different dispensing were added cumulatively. Dividing such a 
cumulative total by 365 days will produce the yearly analysis. 
     
 
Figure 4.4.2.1: Merging of Pharmhouse data from the year 2008 to 2015. 
 




4.4.2.2 Identifying socioeconomic status 
Domicile code, domicile description and NZ deprivation index 2013 obtained from 
different government sources: 
1. Ethnic group table source (https://www.health.govt.nz/nz-health-
statistics/data-references/code-tables/common-code-tables/ethnicity-code-
tables) 
2. Domicile code table source (https://www.health.govt.nz/nz-health-
statistics/data-references/code-tables/common-code-tables/domicile-code-
table) 
3. NZ deprivation index 2013 source 
(https://www.health.govt.nz/publication/nzdep2013-index-deprivation) 
The information of domicile code, domicile description and NZ deprivation index 2013 
was merged to create a single file which was added to Pharmhouse data. This information 
facilitated the tracking of the socioeconomic status of the patient.   
4.4.2.3 Identifying the patients receiving oral hypoglycemics (OHG) 
The Pharmhouse record provides the information about dispensing at the pharmacy 
which ranges from food supplement to injectable products. To avoid unnecessary data 
this study limited the data search only to dispensing of oral (tablet & capsule) 
formulations. As the oral hypoglycemic medication (OHG) is a mainstream treatment for 
T2DM, this study identified the dispensing of metformin (500 mg), metformin (850 mg), 
gliclazide (80 mg), glipizide (5 mg), glibenclamide (5 mg), glibenclamide (2.5 mg), 
pioglitazone (45 mg), pioglitazone (30 mg), pioglitazone (15 mg), tolbutamide (500 mg). 




4.4.2.4 Identifying the OHG patients with co-dispensing 
The dispensing of any medication along with OHG was considered as co-dispensing. 
Patients receiving OHG were screened for co-dispensing of medications over the eight 
years of the period. Count of co-dispensed medication and the therapeutic category was 
determined. The influence of patient demographics on co-dispensing was further 
evaluated.  
 
4.4.3 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. The test of the difference between two proportions was used for all comparisons. 


















4.5. Results  
4.5.1 Nature of Pharmhouse data 
To understand the scope of Pharmhouse records, they were processed in two ways: 
separately for each year and combined for all years from 2008 to 2015.  
 
Figure 4.5.1: Inclusion/exclusion criteria to select the patients receiving OHG for the 
analysis. 
A summary of the data filtering process is shown in Figure 4.5.1 (here data was 
combined for all years from 2008 to 2015). There were 12,405 patients identified with 
OHG dispensing.  
4.5.2 Characteristics of patients with OHG sample and their comparison with 
rest of the patients from Pharmhouse data 
The current study was focused on patients with oral hypoglycemic dispensing. It was 
important to understand if this sample size was different from the rest of the patients in 
the data records. A description of the demographics between patients receiving and not 
receiving OHG is shown in Table 4.5.2.1(a), 4.5.2.1(b) & 4.5.2.1(c). 
   




Table 4.5.2.1(a): Gender & ethnic comparison of the patients with and without OHG. 
 Patients with OHG  
(n=12405) 
Patients without OHG 
(n=327878) 
Count % Count % 
Gender 
Female 5952 48 172450 52.6 
Male 6453 52 155428 47.4 
Ethnicity 
NZ European 6722 54.2 202924 61.9 
Other European 1020 8.25 26446 8.1 
NZ Māori 3354 27 66407 20.3 
Indian 510 4.1 6504 2 
 
The OHG dispensing was higher in male patients (52% vs 47.4%, P<0.001). The OHG 
dispensing was higher in NZ Māori (27% vs 20.3%, P<0.001) & Indian (4.1% vs 2%, 
P<0.001) than NZ European (Table 4.5.2.1(a)). 
 
Table 4.5.2.1(b): Age group-wise comparison of the patients with and without OHG. 
Index age range 
Patients with OHG  
(n=12405) 
Patients without OHG  
(n=327878) 
Count % Count % 
21 to 30 530 4.3 39565 12.1 
31 to 40 992 8 39760 12.1 
41 to 50 1940 15.6 40801 12.4 
51 to 60 2916 23.5 36430 11.1 
61 to 70 3023 24.4 29209 8.9 
71 to 80 2048 16.5 17490 5.3 
81 to 90 681 5.5 8164 2.5 
91 to 100 52 0.4 1166 0.5 




Patients were grouped with different age ranges (Table 4.5.2.1(b)) for the comparison. 
OHG dispensing was low for the age 21 to 40 as compared to dispensing without OHG. 
OHG dispensing rises with higher patient age. The highest OHG dispensing was seen in 
the 61 to 70 age group (24.4%).  
 
Table 4.5.2.1(c): Comparison of the patients with and without OHG at the different 
socioeconomic level. 
NZ Deprivation  
Index 2013 
Patients with OHG  
(n=12405) 
Patients without OHG  
(n=327878) 
Count % Count % 
1 115 1 5868 1.9 
2 592 5.1 19990 6.4 
3 313 2.7 14259 4.7 
4 680 5.9 24321 7.8 
5 1080 9.3 35440 11.4 
6 962 8.3 30525 9.8 
7 1404 12.1 42226 13.6 
8 1929 16.6 46185 14.9 
9 2208 19.1 47603 15.3 
10 2303 19.9 44126 14.2 
(NZ deprivation index 2013, 1 = high income level & 10 = low income level) 
The lower income group patients (socioeconomic deprivation index 8-10) had 
significantly (P<0.001) high rates of OHG dispensing compared with the higher income 
groups (Table 4.5.2.1(c)).   
 




Table 4.5.2.2: The dispensing percentage of OHG agents over the years. 
OHG agent 
Dispensing year 
2008 2009 2010 2011 2012 2013 2014 2015 
Metformin (500 mg) 44.3 45 46.7 49.5 50.9 52.5 54 55.5 
Gliclazide (80 mg) 29.0 29 28.5 27.4 26.6 25.8 25.1 24.1 
Metformin (850 mg) 15.7 14.6 14.1 13.2 13.5 12.9 12.4 12.1 
Glipizide (5 mg) 7.7 8.2 8 7.4 7 7.3 7.4 7.4 
Glibenclamide (5 mg) 1.4 1.2 0.9 0.8 0.6 0.5 0.4 0.3 
Pioglitazone (30 mg) 0.7 0.7 0.8 0.8 0.7 0.4 0.3 0.2 
Pioglitazone (15 mg) 0.6 0.7 0.5 0.4 0.3 0.3 0.3 0.2 
Pioglitazone (45 mg) 0.4 0.6 0.5 0.5 0.4 0.3 0.2 0.2 
Glibenclamide (2.5 mg) 0.2 0.1 0 0 0 0 0 0 
Tolbutamide (500 mg) 0.0 0 0 0 0 0 0 0 




Figure 4.5.2.2: The dispensing percentage of OHG over the years. 
 




There were six oral hypoglycemic agents with different doses. Table 4.5.2.2 represents 
their respective dispensing percentage for each year. Metformin (500 mg), Gliclazide (80 
mg), Metformin (850 mg) and Glipizide (5 mg) were the most common with average 
dispensing percentage of 49.7%, 27.04%, 13.50% and 7.61%. 
 
Table 4.5.2.3: The percentage of co-dispensed medications in the patients with OHG. 
Co-dispensed drugs 
Dispensing year 
2008 2009 2010 2011 2012 2013 2014 2015 
Antihypertensive 22.5 22.5 22.5 22.3 21.4 20.5 20.4 20.1 
Anti-hyperlipidaemic 9.6 9.9 10.1 10.3 10.3 10.3 10.2 10.3 
Anti-thrombotic 7.8 8.4 8.7 8.5 8.3 0.8 7.8 7.7 
Anti-angina  6.2 6.2 6.1 5.9 5.8 5.7 5.5 5.4 
Antacids (GI acidity) 4.2 4.1 4.2 4.3 4.4 4.5 4.6 4.7 
Analgesics 3.1 2.9 2.9 2.8 3.0 3.1 3.1 3.2 
Anti-gout (arthritis) 2.2 2.3 2.3 2.3 2.3 2.2 2.2 2.2 
Anti-asthmatic 1.9 1.8 1.1 1.9 2 2.2 2.5 2.7 
Anti-arrhythmic 1.4 1.2 1.1 1 0.9 0.8 0.7 0.6 
Anti-depressants  1.3 1.4 1.5 1.6 1.8 1.8 1.9 2 
Anti-thyroid agents 1.1 1 1 1 1 1 1 1 
Anxiolytics 1 1 1 1.1 1.2 1.1 1.1 1.1 
 
The percentage of co-dispensed medications in patients with OHG has been reported in 
Table 4.5.2.3. The list was limited to co-dispensed drugs with at least 1 or a higher 
percentage in any year. This included antihypertensive agents, anti-hyperlipidaemias, 
anti-thrombotic agents, anti-angina drugs, antacids (GI acidity), analgesics, anti-gout, 
anti-asthma, antiarrhythmics, anti-depressants, anti-thyroid agents and anxiolytics. 
 




4.5.3 Characteristics of OHG patient with co-dispensing 
 
 
Figure 4.5.3.1: Flowchart to identify OHG patients with co-dispensing. 
 
The process of identifying co-dispensing has been summarised in Figure 4.5.3.1. Co-
dispensing was seen in 88.4% of OHG (n,10742) patients. The co-dispensing percentage 
was reported in Figure 4.5.3.2 for the number of medications ranging from 1 to 6+. The 
percentage of co-dispensing with three and four medications was found to be 21.6% and 















Figure 4.5.3.2: Co-dispensed drug burden in the patients with OHG. 
 
A summary of the demographics for OHG people with and without co-dispensing is shown 
in Table 4.5.3.1. Co-dispensing was significantly higher in male patients (54% vs 38.3%, 
P<0.001) & NZ European ethnic group (55% vs 49.6%, P<0.001). Patients within age 21 
to 50 had significantly low co-dispensing (P<0.001). Whereas older patients from age 51 
to 90 had significantly higher co-dispensing (P<0.001). No influence of socioeconomic 










Table 4.5.3.1: Demographic of OHG patients with and without co-dispensing. 
 With co-dispensing  
(n=10742) 
Without co-dispensing  
(n=1409) 
Count % Count % 
Gender 
Female 4937 46 870 61.7 
Male 5805 54 539 38.3 
Ethnicity 
NZ European 5909 55 699 49.6 
Other European 887 8.3 106 7.5 
NZ Māori 2882 26.8 410 29.1 
Indian 438 4.1 59 4.2 
Index age range 
21 to 30 187 1.7 249 17.7 
31 to 40 548 5.1 291 20.7 
41 to 50 1522 14.2 248 17.6 
51 to 60 2606 24.3 232 16.5 
61 to 70 2896 27.0 160 11.4 
71 to 80 2124 19.8 95 6.7 
81 to 90 753 7.0 47 3.3 
91 to 100 66 0.6 8 0.6 
NZ Deprivation Index 2013 
1 73 0.7 14 1.0 
2 548 5.3 72 5.3 
3 271 2.6 38 2.8 
4 672 6.5 93 6.8 
5 992 9.6 127 9.3 
6 910 8.8 127 9.3 
7 1248 12.1 153 11.2 
8 1742 16.9 221 16.1 
9 1909 18.5 243 17.7 
10 1957 19.0 283 20.6 
(NZ deprivation index 2013, 1 = high income level & 10 = low income level) 
 






Figure 4.5.3.3: Co-dispensing percentage at different age groups of T2DM patients. 
 
Co-dispensing percentage increases with advanced age. The count of co-dispensed drugs 
was higher in the age 61-90 years as compared to 21-60 years (Figure 4.5.3.3).   
 





Figure 4.5.3.4: Classification & contribution of co-dispensed drugs. 
  
 
Figure 4.5.3.5: Further break down of co-dispensed CVS drugs. 
 
There were total 2062119 dispensing records collectively for all the patients with OHG 
(form 1 Jan 2008 to 31 Dec 2015) enlisted in Appendix E with the percentage dispensing 
for each class of the drug. Classification & contribution of co-dispensed drugs from Figure 
4.5.3.4 shows that approximately 50% of the drugs were from cardiovascular (CVS) 
segment. Figure 4.5.3.5 reported the further breakdown of co-dispensed CVS drugs. 





Figure 4.5.3.6: Co-prevalence of co-dispensing in OHG patients (n,10742). 




In the current study, most prevalently co-dispersed drugs were found to be anti-
hypertensive (86.8%), anti-hyperlipidaemic (78.6%), anti-platelet (41.5%), antacids 
(40.7%), analgesics (38%) and anti-angina (33.1%) (Figure 4.5.3.6).    
 
The highest co-prevalent co-dispensing was seen for the combination of anti-
hypertensive and anti-hyperlipidemic (70%), followed by anti-hypertensive and 
antiplatelet (39.1%), anti-hyperlipidemic and antiplatelet (37%), anti-hypertensive and 
antacids (36.9%), anti-hypertensive and analgesics (34.5%), anti-hyperlipidemic and 
antacids (33.6%), anti-hypertensive and anti-angina (32.1%), anti-hyperlipidemic and 





















4.6. Discussion  
Healthcare use, accessibility, or population may be increased in the Bay of Plenty region 
over the years as the number of patients in the Pharmhouse dispensing records kept 
rising every year as did the count of OHG dispensing (Appendix D). Approximately 
82.9% of the patients were seen with OHG dispensing for the subsequent year (indicating 
long-term T2DM treatment). There were 2215 patients receiving OHG dispensing for the 
entire study period of eight years i.e. from 2008 to 2015 without any break. Also, there 
might be some patients who started treatment somewhere during the study period and 
may continue after the study period. Consumption of medication for a long-term 
treatment is essential in chronic disorder like T2DM for the desired therapeutic outcomes 
[319]. Failure to do so may lead to diabetic complications [320]. 
In this study, metformin was found to be the most commonly dispensed oral 
hypoglycemic drug followed by gliclazide and glipizide (Figure 4.5.2.2). This confirms 
the dispensing of OHG as per the guidelines and many professional guidelines are 
recommending metformin for beginning T2DM therapy due to minimum cost and 
established clinical safety over the years [254,320]. The type of OHG therapy (mono or 
combination), the presence of multiple drug regimen (polypharmacy) and its influence 
on medication adherence will be reported in the next chapter. 
The existence of co-dispensing along with OHG dispensing was also observed in this 
study. Table 4.5.2.3 highlights the percentage of each co-dispensed medication class 
existing over the study period. Antihypertensive (21.5%), anti-hyperlipidemic (10.1%), 
anti-thrombotic (7.3%), anti-angina (5.8%), antacids (4.4%) and analgesics (3%) were 
the most prevalent co-dispensed medications. Others included anti-gout, anti-asthmatic, 
anti-arrhythmic, anti-depressants, anti-thyroid agent and anxiolytics.  




The OHG dispensing was higher in male patients, NZ Māori and Indians which coincide 
with the findings of prevalence of diabetes in Indigenous peoples around the globe 
[321,322].  The study used general population data and found that the OHG dispensing 
was recorded in the early age of twenty’s and OHG dispensing was significantly (P<0.001) 
higher in the middle-aged adults and elderly patients. Age group of 61 to 70 has been 
reported with the highest OHG dispensing of 24.4%. 
Socioeconomic status (SES) is an important factor in the population’s health, which is 
derived from occupation, education and financial capacity of an individual [297,323,324]. 
Depending on the strength of SES it can be linked to various health issues 
[325,326,327,328,329,330]. Risk of diabetes is associated with smoking, obesity, junk 
food (unhealthy eating) and physical inactivity, and these are the factors marking low 
socioeconomic levels in the western world [331]. There were studies linking diabetes 
mellitus and lower family income, lower education level, current liability and the amount 
of remaining debt, residential area, region and low occupation jobs [332,333,334,335]. 
Surprisingly, generally accessible and publically funded systems also witnessed impeded 
healthcare access in lower socioeconomic groups because of fewer referrals for specialist 
care and or longer wait times [336,337]. These factors may have been associated with a 
higher incidence of acute diabetic complications reported in patients with low family 
income [336,337,338,339]. As T2DM was found to be more prevalent in lower SES people 
from the developed (high-income) countries [340,341,342,343,344], this study also 
revealed that the lower income group patients (socioeconomic deprivation index 8-10) 
had significantly (P<0.001) high rates of OHG dispensing.   
This study retrospectively examined the Pharmhouse records to determine the drug 
burden of OHG patients within a single New Zealand locality. Further analysis of 
prevalence and co-prevalence of co-dispensing in OHG patient was also done. Our study 




found that 88.5% of the OHG patients were present with co-dispensing. Co-dispensing 
was significantly higher in male patients and NZ European ethnic group. The count of co-
dispensed medication ranges from 1 to 6+ medications. Most patients were receiving 
three (21.6%) or four (20.2%) drugs as co-dispensed medications (Figure 4.5.3.1 & 
4.5.3.2). 
Multiple comorbidities comprising chronic illnesses (e.g. cardiovascular, mental, diabetes 
etc.) joint pains, acute conditions (e.g. viral infections) are prevalent in older age 
[345,346]. Hence, medication count is higher in older patients as compared to young or 
middle-aged adult patients [345,346,347]. In the current study, co-dispensing was highly 
correlated to older age and this finding supports the similar observation from other 
studies [345,347,348,349,350,351]. Not only the co-dispensing prevalence was high from 
age 61-90 years but the count of additional medication was also more as compared to 
lower age (21-60 years). The peak co-dispensing of 6 or more additional medications was 
seen in elderly T2DM patients (age 80 plus years).  
 
Figure 4.5.3.7: Life expectancy of elder people in New Zealand [213]. 




The remaining life expectancy (Figure 4.5.3.7) of older patients need to be considered 
while prescribing additional medication. Polypharmacy is a two-edged sword, especially 
considering the age and health recovery rate. As adults can easily handle the medications 
due to their good metabolic rate and they will show a fast recovery, this is not the same 
in case of elderly patients with mostly compromised metabolic and renal functions. In 
such scenario the addition of a painkiller to an elderly patient’s regimen may be replaced 
with physiotherapy to avoid the drug burden. 
Metabolic disorders are closely associated with obesity [352]. Obesity and Type 2 
diabetes both show the presence of high levels of the non-esterified fatty acids (NEFAs) 
linked to insulin resistance [353,354]. Central (chest & abdominal part) deposition of fat 
causes weight gain and increased insulin resistance leading to diabetes mellitus type 2 
[355]. One diabetic complication of macrovascular nature is atherogenic dyslipidemia 
indicated by increased triglyceride and low-density lipoprotein cholesterol (LDL-C) 
levels [356]. Use of statins and/or lipid-lowering agents is recommended to control 
dyslipidemia in diabetes patients [356,357]. Cardiovascular risk in overweight diabetes 
patients can be reduced with the use of anti-obesity agents as they effectively drop the 
body weight by 5% to 10% and significantly controlled blood glucose levels [358].  
The eighth report of Joint National Committee (JNC-8), the guidelines of the European 
Society of Cardiology (ESC) and of 2013 European Society of Hypertension (ESH) have 
recommended the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin 
II receptor blockers (ARBs) to treat hypertension in patients with diabetes [359,360]. 
Calcium channel blockers, diuretics, and beta-blockers are commonly used to treat 
cardiovascular issues in patients with diabetes [361,362,363,364].




In this study, the prevalence for co-dispensing of antihypertensive and anti-
hyperlipidemic medications along with OHG was found to be 86.8% & 78.6% 
respectively, similar to the results presented in other studies (antihypertensive 
[364,365,366,367], anti-hyperlipidemic [364,368,369]). Whereas, co-prevalence for co-
dispensing of both these classes along with OHG was found to be 70% (Figure 4.5.3.6).      
High rates of co-dispensing indicate the presence of multiple comorbidities. Such 
situations of concomitant therapies may contribute to increased treatment complexity, 
additional healthcare expenses and pill burden which may affect the quality of life and 
may trigger psycho-social disorders [370,371,372,373].  
 
There are some limitations to this study as Pharmhouse data records the dispensing 
funded by Ministry of Health, New Zealand it does not collect any medicine paid for 
privately.  A small number of patients will be receiving OHG for other conditions {i.e. 
metformin for the polycystic ovarian syndrome (PCOS), also some Type 1 diabetes 











4.7. Conclusion  
The OHG patient sample was significantly different from the rest of the patients, most 
likely due to the nature of this disease. This data highlights that OHG dispensing was more 
frequent in males, in NZ Māori, in low-income groups and in patients from age 41 to 90 
years. As expected, patients receiving OHG medications often receive additional 
medications for cardiovascular-related conditions.  Many patients were receiving 3 or 4 
additional medications. Co-prevalence of co-dispensing was also high in patients with 
OHG. Some patients were experiencing polypharmacy (i.e. more than 6 medications) and 
so this may need to be considered. Both age and gender play important role in drug 
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‘Adherence to medications’ indicate the way patients follow the prescribed medication 
instructions, further divided into three quantifiable phases: ‘Initiation’, ‘Implementation’ 
and ‘Persistence’ [63]. 
 
Figure 5.1.1: ABC taxonomy of medication adherence [63] 
Most of the literature published on adherence science is based on clinical trials and lacks 
the evidence of its real world implementation. The same is true with different methods 
for the determination of medication adherence.    
As mentioned in the introductory chapter, there are different measures available to 
calculate medication adherence using healthcare administrative data. The Proportion of 
Days Covered (PDC) and the Medication Possession Ratio (MPR) are the two most 
commonly used measures to estimate medication adherence from secondary databases 
(e.g. electronic dispensing data or claims data) [85,93,94,95,96,97,98]. 
Limitations of medication adherence study based on treatment implementation 
phase: 
Medication possession does not guarantee the consumption of medication. MPR/PDC 
based on pharmacy administrative data may not be able to determine treatment initiation 
non-adherence or discontinuation as they are effective to evaluate treatment 




implementation or persistence.   The accuracy of the data source is important for reliable 
results. Short term analysis (less than 90 days) may result in bias and imprecise outcomes 
[106]. 
Better adherence levels resulting in improved clinical biomarkers (i.e. HbA1c levels or 
lipid profile) has been reported previously in chapter two. In chapter four it was found 
that within the study region a large number of people were receiving oral hypoglycemics 
(OHG) and that there was polypharmacy present. This chapter aims to determine the 
level of non-adherence, and hence the population within the study region that could 
benefit from adherence support, and further begin to identify some individual 
characteristics that may influence adherence to OHG.  
  





The aim of this chapter is to determine medication adherence using surrogate markers 
including proportion of days covered (PDC) and medication possession ratio (MPR) 
derived from pharmacy dispensing records, and to study different factors influencing 
such adherence values. 
This chapter is a compilation of four different studies listed below, using the same data 
set and methodology but with a different research question.  
1. PDC / MPR calculation to determine medication adherence in patients taking oral 
hypoglycemics. 
2. Demographics of adherent and non-adherent patients and the influence of the 
type of therapy (i.e. monotherapy or combination of OHG) on the medication 
adherence.   
3. Influence of drug shift or treatment intensification or different daily doses on the 
medication adherence measurement in OHG patients. 












Study 5.1 PDC / MPR calculation to determine medication adherence in patients 
taking oral hypoglycemics 
This study will establish the baseline data for the subsequent studies.  This will be 
achieved by calculating PDC/MPR as a surrogate marker of medication adherence for the 
OHG patients. The research question here was, how many patients taking oral 
hypoglycaemics were non-adherent?    
5.1.1 Objectives 
a) To explore pharmacy dispensing records over an eight-year period (2008 to 2015) to 
determine surrogate markers for medication adherence (i.e. PDC & MPR) in the patients 
receiving OHG.  
b) To estimate the number of patients that could derive benefit from adherence support 
services based on the degree of adherence (by PDC or MPR). 
5.1.2 Methods 
As mentioned in chapter two this was a retrospective observational study. The request 
was made to the Ministry of Health, New Zealand for the dispensing records of any patient 
that had received an oral hypoglycemic medication from a selected DHB. The e-
dispensing (Pharmhouse) records for selected DHB were then obtained for the period of 
8 years (1st Jan 2008 to 31st Dec 2015). This data provides information including patient 
ID, age, gender, ethnicity, date of dispensing, quantity prescribed/dispensed, daily dose, 
the total number of days’ supply, chemical & therapeutic ID of the drug. As disclosed in 
the earlier chapter there were total 340,283 patients in the Pharmhouse records. Out of 
those, 12405 patients were identified with OHG dispensing. These patients will be further 
analyzed for the adherence based on their medication possession ratio or proportion of 
days covered.  




5.1.3 Calculation of PDC and MPR 
Adherence to the OHG was the primary outcome of interest which was assessed by 
calculating the PDC or MPR for each patient. The nature of medication refill is highlighted 
by this ratio (e.g. how often patients refill their medications).  
PDC was defined as a ratio of the proportion of days covered in a year with OHG 
medication and calculated using the following equation [92]:  
PDC =
D × 100
365 –  1
 
Here “D” is a number of days on which the patient has the medication available (e.g. total 
days’ supply – any overlapping supply from early fills). “– 1” was for a day of last 
dispensing. 
MPR was defined as a ratio of the total day’s supply in a year with OHG medication and 
calculated using the following equation [92]:  
MPR =
D × 100
365 –  1
 
Here “D” is a number of days for which a patient had the medications collected (e.g. total 
days’ supply). “– 1” was for a day of last dispensing. 
MPR values greater than 100% were capped to 100. Such an “excess fill” are seen due to 
early refill by patients. Capping to 100 is necessary to avoid undesired inflation of average 
MPR [95]. A PDC/MPR ≥ 80% is a commonly accepted index of adherence 
[56,85,94,108,231,285]. Complete benefits of the medications could be expected in 
chronic treatment with therapy if patients had at least 80% adherence [285]. 
5.1.4 Identifying OHG patients for adherence analysis 
A follow-up dispensing record is essential to calculate medication possession ratio. 
Therefore, patients were excluded from further analysis if they had only one dispensing 




recorded (missing follow-up dispensing). As explained earlier in chapter four, the 
cumulative days were marked by 365-day interval to get the year value (e.g. cumulative 
days ≤ 365 is the 1st year, cumulative days between 366 & 730 is a 2nd year, and so on). 
There were patients with follow-up dispensing data recorded up to eight years.    
 
 
Figure 5.1.4: Capping the observation period to second last year for yearly PDC/MPR 
analysis.  




In the last year, the cumulative days may be less than 365 as dispensing records may be 
available for only a few months (Figure 5.1.4). Such incomplete data may lead to the 
calculation of false PDC/MPR in the last year of study and may influence the average value 
of PDC/MPR for overall study years. Hence the PDC/MPR analysis period was capped up 
to last full/complete year to avoid false medication adherence.   
5.1.5 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. The test of the difference between two proportions was used for all comparisons. 
Statistical significance was taken to be P < 0.05.  
 
 




5.1.6 Results  
There were 12,405 patients with OHG dispensing over the study period (Figure 5.1.6). 
Both the proportion of days covered and the medication possession ratio (MPR) were 
calculated for the patients with OHG to estimate the medication adherence. 1,775 
patients were excluded from further analysis as they had only one dispensing recorded 
(missing follow-up dispensing). There were 3,492 patients excluded while capping the 
observation period to second last year {(1,973 + 1,519 = 3,492) here 1,973 patients did 
not have a full/complete year of dispensing (so failing to get average PDC/MPR) and 
1,519 patients had two years’ observation where capping to second last year left them 
with only the first year’s observation failing to get average PDC/MPR over the years}. 
At the end there were 7,138 patients for the analysis. 
 
 








5.1.6.1 PDC / MPR based medication adherence in OHG patients  
The count and the average value of PDC & MPR at different study periods are summarized 
in Table 5.1.6.1. In comparison with PDC (≥ 80%), MPR (≥ 80%) values were higher in 
the overall study period (69.9% vs 76.8%) and capped to the second yearly analysis 
(45.5% vs 59.6). 
 
Table 5.1.6.1: Comparing PDC/MPR in patients receiving OHG over the different study 
period.  
 Average PDC / MPR  











Overall 8 years without 
capping (n= 10603) 
Count 3204 7426 2469 8161 
% 30.1 69.9 23.2 76.8 
Overall 8 years capped  
to 2nd last year  
(n= 7138) 
Count 3892 3246 2882 4256 
% 54.5 45.5 40.4 59.6 
 
Here onwards, only PDC observations capped to the second last year of dispensing were 
considered for the analysis. This is because PDC is a validated and time-tested quality 
measure for medication adherence calculation at the population level and also 
recommended by Pharmacy Quality Alliance (PQA) and The Centres for Disease Control 
and Prevention (CDC) which are the recognized institutes in the USA working for public 








The spread of PDC values over the ranges from < 50% to 100% are summarized in Table 
5.1.6.2.  Extreme non-adherence (PDC < 50%) was significantly (P<0.001) higher in the 
eighth year (31.1%) as compared to the first year (26%), whereas complete adherence 
(PDC ≥ 90%) was significantly (P<0.001) higher in the first year (46.2%) as compared to 
the eighth year (17.6%).    
 
Table 5.1.6.2: Spread of PDC for every dispensing year in patients receiving OHG.  
Year of 
dispensing 
Patient (%) with respective PDC range  














First 26 3.8 5.5 10.5 8.0 46.2 10207 
Second 27.3 3.9 7.4 15.6 10.9 34.9 7446 
Third 26.5 4.2 7.5 14.2 12.0 35.6 6411 
Fourth 25.7 3.9 7.5 14.5 12.6 35.9 5409 
Fifth 27.8 4.0 6.8 14.6 13.0 33.9 4573 
Sixth 25.8 4.4 7.3 14.2 12.9 35.3 3755 
Seventh 27.5 3.7 7 15.7 13.3 32.8 3010 












A visual representation of PDC-based adherence in the patients with OHG, where black 
lines indicate non-adherence and red lines indicate adherence is shown in Figure 5.1.6.2. 
The overall adherence (PDC ≥ 80%) in OHG patients was high (54.2%) in the first year, 
and kept dropping over the following years until dropping very low (30%) in the 8th year.  
The overall non-adherence (PDC < 80%) in OHG patients was low (45.8%) in the first 
year and kept rising over the following years. It reached its highest (70%) in the 8th year. 
 
 
Figure 5.1.6.2: Spread of PDC for every dispensing year in patients receiving OHG 










Study 5.2 Demographics of adherent and non-adherent patients and influence 
of the type of therapy (i.e. monotherapy or combination of OHG) on the 
medication adherence  
This part of the chapter will identify the influence of individual demographics and the 
influence of monotherapy or a combination of OHG on the medication adherence 
estimated by PDC in OHG patients.  
5.2.1 Objective 
To identify demographic characteristics (regarding age, gender, ethnicity and 
socioeconomic status) of adherent (PDC ≥ 80%) and non-adherent (PDC < 80%) OHG 
patients. To study the influence of the type of therapy on the medication adherence of 
OHG patients. 
5.2.2 Methods 
Adherence to the OHG was the primary outcome of interest, which was assessed in the 
study 5.1 by calculating the PDC for each patient. The nature of medication refill was 
highlighted by this ratio (e.g. how often patients refill their medications). 
In study 2, the two categories of information were studied: 
1) patient characteristics including gender, ethnicity, age group/range and 
socioeconomic deprivation index (assigned by the New Zealand Government) and,  
2) type of therapy e.g. monotherapy, a combination of two or three medications.   
5.2.3 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. The test of the difference between two proportions was used for all comparisons. 
Statistical significance was taken to be P < 0.05.





5.24.1 Demographics of 7138 patients subjected to adherence (PDC) analysis  
 
Table 5.2.4.1: Demographics of OHG patients with PDC < 80% and with PDC ≥ 80%. 
 PDC < 80% 
(n=3892) 
PDC ≥ 80% 
(n=3246) 
Count % Count % 
Gender 
Female 1788 46.0 1517 46.7 
Male 2103 54.0 1729 53.3 
Ethnicity 
NZ European 1879 48.3 2090 64.4 
Other European 297 7.6 295 9.1 
NZ Māori 1295 33.3 651 20.1 
Indian 185 4.8 92 2.8 
Index age range  
21 to 30 83 2.1 23 0.7 
31 to 40 281 7.2 76 2.3 
41 to 50 728 18.7 331 10.2 
51 to 60 1083 26.7 693 21.3 
61 to 70 967 24.9 1017 31.3 
71 to 80 599 15.4 833 25.7 
81 to 90 169 4.3 249 7.7 
91 to 100 7 0.2 19 0.6 
NZ Deprivation Index 2013 
1 20 0.5 13 0.4 
2 191 5.1 185 6.0 
3 78 2.1 76 2.4 
4 191 5.1 246 7.9 
5 366 9.9 307 9.9 
6 305 8.2 251 8.1 
7 434 11.7 369 11.9 
8 656 17.7 546 17.6 
9 720 19.4 530 17.1 
10 749 20.2 582 18.7 
(NZ deprivation index 2013, 1 = high income level & 10 = low income level) 




The demographics for the sub-set of OHG patients with PDC < 80% and PDC ≥ 80% are 
listed in Table 5.2.4.1. Of the 3,892 OHG patients in the sample who were non-adherent 
(PDC <80%), 54.0% were men, 33.3% were NZ Māori, most from the age between 21 to 
60 years and mainly from the lower socioeconomic background (NZ Depr. Index 9 & 10). 
5.2.4.2 Adherence (PDC) analysis based on type of therapy  
The spread of PDC values over the ranges from < 50% to 100% is shown in Table 5.2.4.2.  
The patients taking OHG as a combination of three medications were found to be extreme 
non-adherent (PDC < 50%) and their count (41.9%) was significantly (P<0.001) higher, 
than those taking OHG as combination two (19.4%) or monotherapy (5.5%). By contrast, 
complete adherence (PDC ≥ 90) was significantly (P<0.001) higher in OHG monotherapy 
(37.3%) as compared to the combination of three (8.6%) and two (1.0%). 
Table 5.2.4.2: Spread of PDC values in patient receiving OHG (n= 7138). 
Patient 
characteristic 
Patient count with respective PDC range (n, %)  











































































Based on the type of therapy i.e. monotherapy, a combination of two and a combination 
of three OHG, the non-adherence was found to be 34.6%, 74.7%, and 92.3% respectively. 




Study 5.3: Influence of drug shift or treatment intensification or different daily 
doses on the medication adherence in OHG patients 
  
5.3.1 Objective 
To determine the influence of drug shift, treatment intensification and different daily 
doses on the medication adherence estimated by PDC in OHG patients. 
5.3.2 Methods 
In this study, 7,138 OHG patients were further analyzed for the drug shift in their follow-
up dispensing as follows: 
a) in the case of monotherapy if the OHG drug was changed in subsequent 
dispensing, then that was noted as drug shift., 
b) in the case of combination therapy, the addition of the new OHG drug was 
considered as drug shift or intensification.  
The influence of such a drug shift on the PDC was studied. The effect of treatment type 
(e.g. monotherapy or combination) and daily dose on the medication adherence was also 
studied. 
5.3.3 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. The test of the difference between two proportions was used for all comparisons. 
Statistical significance was taken to be P < 0.05.





5.3.4.1 Demographics of OHG patients with and without drug shift  
Table 5.3.4.1: Demographics of OHG patients with and without drug shift 
 Patient with  
Drug shift 
(n=4395) 
Patient without  
Drug shift 
(n=2743) 
Count % Count % 
Gender 
Female 1967 44.8 1338 48.8 
Male 2428 55.2 1405 51.2 
Ethnicity 
NZ European 2372 54.0 1598 58.3 
Other 
European 
366 8.3 226 8.2 
NZ Māori 1252 28.5 694 25.3 
Indian 185 4.2 92 3.4 
Index age range 
21 to 30 63 1.4 43 1.6 
31 to 40 250 5.7 107 3.9 
41 to 50 725 16.5 334 12.2 
51 to 60 1118 25.4 613 22.3 
61 to 70 1208 27.5 776 28.3 
71 to 80 791 18.0 641 23.4 
81 to 90 214 4.9 205 7.5 
91 to 100 13 0.3 13 0.5 
NZ Deprivation Index 2013 
1 21 0.7 12 1.0 
2 213 5.3 163 5.3 
3 96 2.6 58 2.8 
4 244 6.5 193 6.8 
5 431 9.6 242 9.3 
6 327 8.8 230 9.3 
7 503 12.1 300 11.2 
8 722 16.9 480 16.1 
9 785 18.5 465 17.7 
10 826 19.0 505 20.6 
(NZ deprivation index 2013, 1 = high income level & 10 = low income level) 




In the case of monotherapy, if the OHG drug was changed in subsequent dispensing then 
that was noted as drug shift and in the case of combination therapy, the addition of a new 
OHG drug was considered as drug shift or intensification. There were 4,395 (61.6%) 
patients with drug shift and ,2743 (38.4%) without drug shift in their subsequent OHG 
dispensing.  A description of the demographics for these patients was highlighted in 
Table 5.3.4.1.  It reveals that OHG drug shift use was higher in male patients (55.2% vs 
51.2%, P<0.001), in NZ Māori (28.5% vs 25.3%, P<0.001) and those patients between age 
41 and 60 (P<0.001). Drug shift was lower in NZ Europeans and elderly patients (age 71 
& above). Drug shift was not influenced by socioeconomic status. 
    
5.3.4.2 Adherence (PDC) analysis in patients with OHG drug shift   
In this study, 69.8% (3070 out of 4395) of the patients with OHG drug shift was found to 
be non-adherent (PDC < 80%). Based on the type of therapy i.e. monotherapy, a 
combination of two and a combination of three OHG, the non-adherence was found to be 
42.2%, 77.4%, and 93.3% respectively. 
Table 5.3.4.2: Spread of PDC values in patients with drug shift (n= 4395). 
Patient grouped 
as per treatment 
type 
Patient count with respective PDC range (n, %)  































































The spread of PDC values in over the ranges from < 50% to 100% are summarized in 
Table 5.3.4.2. The patients taking OHG as a combination of three medications were found 
to be extreme non-adherent (PDC < 50%) and their count (42.9%) was significantly 
(P<0.001) higher, than those taking OHG as combination two (20.9%) or monotherapy 
(7.5%). Whereas complete adherence (PDC ≥ 90) was significantly (P<0.001) higher in 












Intensification of OHG treatment was observed in 2,273 (51.7%) of drug shift cases. The 
further breakdown of PDC spread in such cases is reported in Table 5.3.4.3. 82.1% of the 
treatment intensification cases were found to be non-adherent. 
 
Table 5.3.4.3: Spread of PDC values in patients with treatment intensification (n= 2273). 
Patient grouped 
as per treatment 
type 
Patient count with respective PDC range (n, %)  

































Figure 5.3.4.3: Spread of PDC values in patients with treatment intensification  
(n= 2273). 
 




5.3.4.4 Adherence (PDC) analysis in patients with non-drug shift in their OHG 
regimen 
In this study, 31.1% (852 out of 2743) of the patients with non-drug shift were found to 
be non-adherent (PDC < 80%). Based on the type of therapy, the non-adherence was 
found to be 31.7% (monotherapy), and 14.9% (a combination of OHG). In non-drug shift 
cases, monotherapy with OHG was prevalent (96.3%; 2642/2743). Therefore, this study 
further investigated the daily dose of OHG in monotherapy and respective PDC. The non-
adherence was found to be 34.1%, 33.4% and 27.9% for the daily doses of three/three+, 
two and single doses respectively. 
 
 
Figure 5.3.4.4: Daily dose/s and spread of PDC values in monotherapy patients with 
non-drug shift (n=2642). 
 
 




The spread of PDC values in over the ranges from < 50% to 100% are summarized in 
Table 5.3.4.4.  Extreme non-adherence (PDC < 50%) was significantly (P<0.001) higher 
in patients with daily doses of three/three+ (5.5%) & two (5.6%) as compared to single 
dose (3.3%). Whereas complete adherence (PDC ≥ 90) was significantly (P<0.001) higher 
with single daily dose (44.8%) as compared to daily doses of three/three+ (38.7%) and 
two (34.1%). 
 
Table 5.3.4.4: Daily dose and spread of PDC values in monotherapy patients with non-
drug shift (n= 2642). 
Patient grouped 
as per daily dose 
Patient count with respective PDC range (n, %)  


































































Study 5.4: Influence of polypharmacy on the medication adherence in OHG 
patients 
This part of the chapter will study the influence of polypharmacy on the medication 
adherence estimated by PDC in OHG patients. 
5.4.1 Objective 
To determine the influence of polypharmacy on the medication adherence estimated by 
PDC in patients taking OHG in the study group. 
5.4.2 Methods 
In this part of the study, the presence of polypharmacy in patients with OHG was also 
considered and studied for its correlation with PDC/MPR. The concurrent dispensing of 
5-9 drugs was considered as polypharmacy and dispensing of 10 or more as ‘Excess’ 
polypharmacy, whereas dispensing of up to 4 drugs was considered non-polypharmacy 
[48,291,292,293]. Each patient was assigned with an average yearly polypharmacy status 
as there were multiple dispensing records and every dispensing with independent 
polypharmacy label. The change in polypharmacy over the following years was compared 
to the index year’s polypharmacy status. 
5.4.3 Data analysis 
Microsoft Excel and IBM SPSS Statistics version 23 were used to collate and analyze the 
data. The test of the difference between two proportions was used for all comparisons. 










Table 5.4.4.1: Demographics of OHG patients with different polypharmacy status (n= 
7138). 




















Total count (n) 3866 1315 822 504 323 188 120 
Gender (%)        
Female 45.7 45.2 44.9 48.6 50.2 54.3 54.2 
Male 54.3 54.8 55.1 51.4 49.8 45.7 45.8 
Ethnicity (%)     
NZ European 50.2 58.9 60.1 64.1 67.8 69.7 74.2 
Other European 7.8 7.9 11.1 8.7 7.1 9.6 7.5 
NZ Māori 30.9 26.4 21.0 23.0 21.1 17.0 14.2 
Indian 4.6 2.9 4.4 2 2.2 27 2.5 
Index age range (%)    
21 to 30 2.6 0.2 0.2 0.2 0.0 0.0 0.8 
31 to 40 8.1 1.9 1.8 0.4 0.3 0.0 0.0 
41 to 50 20.2 11.3 9.0 4.8 5.6 2.1 6.7 
51 to 60 26.7 25.8 20.4 18.5 16.1 14.4 15.0 
61 to 70 24.0 33.2 33.8 32.9 29.1 25.5 28.3 
71 to 80 14.4 20.8 26.5 32.7 36.5 33.0 32.5 
81 to 90 3.1 6.4 7.9 9.7 11.8 23.9 15.8 
91 to 100 0.3 0.4 0.2 0.6 0.6 1.1 0.8 
NZ Deprivation Index 2013 (%)    
1 0.3 1.1 0.6 0.0 0.3 0.0 0.0 
2 5.4 5.3 5.8 6.3 6.2 5 5.3 
3 2.6 2.2 2.1 1.5 1.3 1.1 1.8 
4 6.1 7.5 6.9 5.9 5.5 6.7 7.1 
5 9.2 9.8 11.0 12.1 10.4 11.7 10.6 
6 7.6 8.7 9.1 8.4 7.5 10.1 12.4 
7 11.6 10.9 13.2 14.2 12.0 9.5 8.8 
8 17.2 17.0 16.5 18.0 21.1 25.7 23.9 
9 18.1 18.8 18.5 16.9 20.8 16.2 23.9 
10 21.9 18.7 16.2 16.7 14.9 14 6.2 
(NZ deprivation index 2013, 1 = high income level & 10 = low income level) 




A description of the demographics of OHG patients with different polypharmacy status 
are highlighted in Table 5.4.4.1.  Out of 7138 OHG patients, 3866 (54.1%) were present 
with non-polypharmacy (0-4 drugs), 3152 (44.2%) had polypharmacy (5-9 drugs) and 
120 (1.7%) had excess polypharmacy (10 ≥ drugs).    
The percentage of non-polypharmacy in male patients was found to be 54.3% and that of 
polypharmacy with 5,6,7 drugs was 54.8%, 55.1%, 51.4% respectively. The percentage 
of polypharmacy with 8, 9 drugs and excess polypharmacy (10 or more drugs) was found 
to be 50.2%, 54.3%, 54.2% in female patients. 
In NZ European patients, the percentage of polypharmacy and excess polypharmacy was 
found to be 64.12% and 74.2%, which was 13.92% and 24% higher as compared to non-
polypharmacy (50.2%). The polypharmacy percentage was increased by an average of 
2.7% with the additional drug. In NZ Māori patients, the percentage of non-
polypharmacy, polypharmacy, and excess polypharmacy were found to be 30.9%, 21.7%, 
and 14.2%. The percentage of polypharmacy and excess polypharmacy was found to be 
higher as compared to non-polypharmacy in following age groups; 61 to 70 (30.9% & 
28.3% vs 24%), 71 to 80 (29.9% & 32.5% vs 14.4%), 81 to 90 (11.9% & 15.8% vs 3.1%) 
and 91 to 100 (0.6% & 0.8% vs 0.3%). 
Most of the polypharmacy and excess polypharmacy patients belong to a 
socioeconomically deprived class (represented by 6, 8 & 9 on NZ deprivation Index 2013). 
The percentage of polypharmacy and excess polypharmacy was found to be higher as 
compared to non-polypharmacy in the following cases, with NZ deprivation Index as 6 
(8.7% & 12.4% vs 7.6%), Index as 8 (29.7% & 23.9% vs 17.2%) and Index as 9 (18.2% & 
23.9% vs 18.1). Surprisingly, the patients with NZ Deprivation Index 10 had contrasting 
findings where non-polypharmacy (21.9%) was higher as compared to polypharmacy 
(16.1%) and excess polypharmacy (6.2%).  




Non-polypharmacy (62.1%) and excess polypharmacy (60%) had the most sustained 
status over the study period as compared to index year’s status (Table 3.12). The addition 
of a drug/s over the follow-up dispensing was seen with 45.7% of the patients, who had 
polypharmacy status at index year. The highest notable drop was seen in the 
polypharmacy with 9 drugs patients (41.5%) followed by excess polypharmacy patients 
(40%). 
 
Table 5.4.4.2: Change in polypharmacy status during follow-up year dispensing (n= 
7138). 
Index status vs 
change in follow 
up years 




















Sustained 62.1 31.8 29.3 26.4 27.6 19.1 60.0 
Raised 37.9 51.3 50.7 46.4 40.6 39.4 0.0 
Fall 0.0 17.0 20.0 27.2 31.9 41.5 40.0 
Total count (n) 3866 1315 822 504 323 188 120 
 
Based on the polypharmacy status i.e. Non-poly, Poly with 5, Poly with 6, Poly with 7, Poly 
with 8, Poly with 9 and Excess polypharmacy (10 or 10+), the non-adherence (PDC < 
80%) was found to be 60.9%, 49.5%, 46.8%, 47.7%, 41.8%, 43.1% and 37.5% 
respectively.  
The spread of PDC values in over the ranges from < 50% to 100% is summarised in Table 
5.4.4.3.  The patients with non-polypharmacy, were found to be extreme non-adherent 
(PDC < 50%) and their count (15.8%) was significantly (P<0.001) higher, than patients 
with Poly with 5 (11%) or other polypharmacy patients; whereas complete adherence 




(PDC ≥ 90) was significantly (P<0.001) higher in excess polypharmacy (35.9%) & Poly 
with 9 cases as compared to non-polypharmacy (18.6%). 
Table 5.4.4.3: Spread of PDC values in patients with polypharmacy (n= 7138). 
Polypharmacy 
status 
Patient count with respective PDC range (%)  













Non-poly 15.8 11.4 14.5 19.2 20.5 18.6 3866 
Poly with 5 11 8.6 12.5 17.4 24.9 25.6 1315 
Poly with 6 8.2 7.3 12.4 19.0 24.8 28.3 822 
Poly with 7 7.9 8.1 12.5 19.2 23.6 28.6 504 
Poly with 8 7.1 7.4 12.7 14.6 24.5 33.4 323 
Poly with 9 6.4 8.0 9.6 19.1 21.3 35.6 188 
Poly with 10 or 
10+ 
6.7 2.5 10 18.3 25.8 35.8 120 
 
 
Figure 5.4.4.3: Spread of PDC values in patients with different polypharmacy status  
(n= 7138). 





5.5.1 PDC / MPR calculation to determine medication adherence in patients 
taking oral hypoglycemics 
Oral hypoglycemic medications are the mainstay therapy of Type 2 diabetes Mellitus in 
conjunction with diet and exercise modifications [374,375,376].  However, it is 
recognized that adherence to these medications continues to be suboptimal [377,378] 
and therefore improving patient adherence to these medications draws interest [379].  
One driver for increasing adherence as a strategy is that there is clear evidence that 
increased adherence to these medications can improve clinical outcomes [259,260,380]. 
Inadequate adherence to chronic medication therapy can be challenging [56,231,263] 
and is a recognized problem that needs to be addressed to ensure that the benefits of 
medication can be achieved [381,382].  For this reason, adherence support services are 
increasing internationally [232] and individualized strategies may increase medication 
adherence [232,233].  Results from chapter two showed that Type 2 diabetes patients 
who received adherence support improved their adherence scores and subsequently 
reduced their HbA1c levels.  However, what is unknown is how many other Type 2 
diabetes patients would benefit from access to this service, and specifically what the 
adherence level is within the local population. 
Evaluating the PDC/MPR (as a surrogate marker for adherence) collectively over the 
study period at once may lose the information on the change in adherence over the 
time/period. In the literature, different time frames were reported to measure adherence 
and the most frequently used is 12 months [383]. Adherence evaluation using pharmacy 
administrative data can be effectively done by using a yearly time frame.  The long-term 
treatment of Type 2 diabetes mellitus demands follow-up refill of OHG medication for 




optimal outcomes. The adherence rate was significantly higher in the first year but kept 
decreasing over time whereas non-adherence was low in the first year and kept 
increasing with each further year (Figure 5.1.6.2). These findings are similar to the other 
studies in literature which reported that good adherence in the beginning years of 
treatment may worsen over the subsequent 1–5 years [384,385,386]. 
There are studies reporting that pharmacist intervention can improve medication 
adherence and treatment outcomes (glycemic control) in Type 2 diabetes patients 
[387,388,389,390,391,392,393,394]. The existence of 54.5% of non-adherence in OHG 
patients from the current study may warrant such an adherence support services for 
them.  
5.5.2 Demographics of adherent & non-adherent patients and influence of the 
type of therapy (i.e. monotherapy or combination of OHG) on the medication 
adherence 
Non-adherence was significantly higher in NZ Māori ethnic group, in the young and 
middle aged, and in patients with low socioeconomic status. Considering the chronic 
nature of Type 2 diabetes disorder, the treatment intensification may demand an addition 
of one or more drugs to the current monotherapy (or the non-responsive beginner 
monotherapy). This additional OHG may trigger treatment non-adherence as the study 
demonstrated that the spread of non-adherence was notably higher in therapy with a 
combination of OHG than monotherapy. Such non-adherence may complicate the disease 
progression, raise the chances of comorbidity, invite expensive health management and 
may lead to death [395]. 
There are studies reporting low medication adherence in patients with 
socioeconomic disadvantage [396,397]. Current findings of non-adherence in patients 




with low socioeconomic status support these studies.  Race and socioeconomic 
disadvantage are coexistent factors for non-adherence [398]. Lower adherence rates in 
African-American patients were reported as compared with white patients [399,400]. 
These observations are similar to the non-adherence observed in NZ Māori ethnic group 
as compared to NZ Europeans.   
New Zealand primary healthcare accessibility may be influenced by ethnicity [401] and 
socioeconomic status [402]. This might be one of the reasons that the patients who 
identified as Māori were non-adherent. Low-income patients may hesitate to refill their 
medications due to the financial barrier, hence resulting in treatment non-adherence. In 
order to afford the medication cost, poor patients may choose low nutritional, low-cost 
food options [402] which may trigger high blood glucose levels.  
The findings of non-adherence in patients younger than 60 years are similar to other 
published studies [403,404,405]. Being non-adherent in the age groups between 21 and 
60 will be a major concern as these patients are in an ‘actively working’ category. Poor 
glycemic control will affect the working ability/productivity of a person and may invite 
hospitalization and additional healthcare cost. Interestingly, the patients over 60 showed 
reasonable adherence to OHG therapy. A meta-analysis has also shown that that 
adherence can be better in older patients [406].  This may be due to them becoming 
accustomed to their medications as they are taking it for a long time, and such an 
established routine reminds them to take medication on time [407]. 




5.5.3 Influence of drug shift or treatment intensification or different daily doses 
on the medication adherence measurement in OHG patients 
5.5.3.1 Adherence analysis in OHG drug shift cases (n= 4395) 
The PDC-based rate of non-adherence was significantly higher (69.8%) in OHG patients 
who were subjected to treatment alteration, either by replacing the existing OGH drug or 
by addition of a new OHG drug to existing regimen. The type of treatment (monotherapy 
or combination) has a significant influence on the PDC-based medication non-adherence. 
As shown in Figure 5.3.4.2 & Figure 5.3.4.3, the OHG combination treatment regimens 
and treatment intensification cases fall mostly in the non-adherence (PDC < 80%) spread 
region. These results are coinciding with the published studies reporting non-adherence 
in combination therapy [408,409]. Treatment modifications are inevitable in case of poor 
therapeutic outcomes by existing regimen [410]. The change or addition of a new drug to 
the treatment is not always well received by patients as it may lead to adverse 
events/side effects [411]. This may discourage patients from refilling the prescription or 
completely stop to consume them [412]. Drug shift may create some confusion in aged 
population about the use of a drug, or the lack of knowledge of its effectiveness may 
prevent them from accepting the modified prescription. This altogether may lead to 
lower medication adherence as shown by drug shift cases PDC analysis in this study. 
5.5.3.2 Adherence analysis in OHG non-drug shift cases (n, 2743) 
Non-adherence was lower in non-drug shift cases (31.1%) as compared to drug shift 
cases (69.8%). Monotherapy with OHG was prevalent in these patients, hence non-
adherence was determined on the basis of daily dose.  
This study showed a significant influence of a daily dose/s of OHG on the PDC based 
medication non-adherence. As shown in Table 5.3.4.4 the daily doses of two or more 




tablets can be linked to lower PDC values. These findings are similar to existing 
systematic reviews and meta-analyses [413,414].  
5.5.4 Influence of polypharmacy on the medication adherence measurements in 
OHG patients  
Not only was the polypharmacy higher in NZ European patients but its percentage also 
kept rising with the increase in the number of drugs (Table 5.4.4.1). The older 
population, being vulnerable to many complex disorders, may need multiple medications 
for optimal clinical benefits, which may increase the drug burden.  
Many published studies reported non-adherence in patients with polypharmacy 
[124,125,230,415,416,417,418,419]. Contrary to these studies, the current study 
observed that there was an increased adherence in patients with polypharmacy and 
excess polypharmacy. This could be because older patients or patients on multiple 
medications or older patients with complex drug regimens are mostly subjected to 
adherence interventions [420,421,422,423,424].  Improved medication adherence in 
older patients was observed with the use of medication aids (using a pillbox or a 
calendar) [425,426]. Event-based (taking medications at bedtime or with meals) and 












5.5.5 Limitations of the secondary adherence study  
There are some limitations to this study as Pharmhouse data records the dispensing 
funded (subsidised) by Ministry of Health, New Zealand and it does not collect any 
medicine paid for privately.  A small number of patients will be receiving OHG for other 
conditions (i.e. metformin for PCOS, also some type 1 diabetes patients receive OHG in 
addition to insulin). Pharmhouse data represents only the collection of medication. The 
fate of dispensed drugs is still unknown as there is no information about its 
administration. The values found in this study may underestimate the true non-









The adherence rate was significantly higher in the first year but kept decreasing over the 
time. Non-adherence to OHG medications was significant (54.5%) and widespread in the 
Bay of Plenty DHB.   
Non-adherence (PDC < 80%) was significantly high in combination therapy, indigenous 
ethnic group (NZ Māori) and patients between 21 to 60 years of age. Prescribers need to 
be encouraged to optimize monotherapy before the addition of another OHG, and 
adherence support services should not only be offered to older patients. 
The daily doses of two or more tablets can be linked to medication non-adherence. 
Change in the OHG treatment regimen may lead to medication non-adherence especially 
with the addition of a new drug to current therapy (combination vs monotherapy).  
OHG patients with polypharmacy had high chances of staying with multiple medications 
and non-polypharmacy OHG patients may get the addition of drug/s to their treatment 
with further years.  
Polypharmacy and excess polypharmacy was significantly higher in older patients. The 
patients with poly and excess polypharmacy were more adherent (PDC ≥ 80%) than non-
polypharmacy patients.  
 
 









General discussion, general conclusion 
















6.1 General discussion 
The current research presented in this thesis was inspired by the challenges in the field 
of medication adherence. A specific focus of this work was the understanding of 
adherence and adherence support in a “real world” population, rather than in those 
selected for a research study. This thesis has reported an impact of pharmacist-led 
adherence support on patient adherence and clinical outcomes in a real world population. 
The original findings are mainly relevant to the NZ DHB context. Though some findings 
are DHB-specific, the overall insight gained is also relevant to pharmacist-led service 
more broadly. 
The work was initiated by studying the influence of adherence support service 
(Medication Use Review, MUR) on a small number of patients in a single locality in New 
Zealand. In chapter two, the changes in the medication adherence levels after MUR visit 
were recorded. Further, the adherence levels (MUR subjective scores) of patients with 
T2DM were correlated to clinical biomarker (HbA1c) to determine the influence of MUR 
on actual clinical outcomes (as a higher MUR adherence score should lower the HbA1c 
level over time). The findings may add to the scarce literature on medication review and 
clinical outcome data from the real world population. 
Chapter three was based on a study to determine the feasibility of analysing routinely 
collected health information for the long term evaluation of MUR service and to correlate 
subjective MUR adherence scores with objective adherence determined by the proportion 
of days covered (PDC). This is a unique study of its kind and may allow the feasibility to 
be determined and, in addition, will generate data that will allow prediction of numbers 
needed in future power calculations. 




Not all patients can receive adherence support services, so use of a large dataset (e.g. 
pharmacy collection data) may provide insights into how widespread the adherence issue 
is and how many may benefit from such a service. There are some non-invasive methods 
reported in the adherence science literature, which can be fast, reliable, inexpensive and, 
most importantly, based on real-world data. Chapter five used one such method (i.e. 
calculation of proportion of days covered using pharmacy administrative / collections 
data) as a surrogate adherence marker. The findings from this study may provide an 
insight into the spread of non-adherence in the patients taking OHG within the study 
region. 
A major portion of the current thesis was based on the evaluation of a pharmacy 
administrative data (Pharmhouse data, Ministry of New Zealand) to determine 
medication adherence in patients taking oral hypoglycaemics. The factors associated with 
medication non-adherence in such patients were further studied.  One of the studies from 
chapter four also emphasised the drug burden (co-dispensing) for patients taking oral 
hypoglycaemics as a complex drug regimen (polypharmacy), as it may influence 
medication adherence. This was further established in study 5.4 of chapter five.       
 
6.1.1 The influence of pharmacist-led adherence support on medication 
adherence and clinical biomarkers 
6.1.1.1 Medication adherence and real world data 
As discussed in the introductory chapter many countries are recognizing the importance 
of improving medication adherence and have initiated services to improve adherence. 
There are many studies published internationally reporting on the satisfactory 




performance of medication review services but there is little outcome data 
[130,132,213,217,218,219237,238,409,410]. Further, the studies with outcome data 
were mainly conducted in a study population (with a defined inclusion/exclusion 
criterion, to receive an intervention) rather than in a group of patients all of whom 
received a government funded service [241,245,246,247].  
The study findings from chapter two adds to the international literature about both the 
direct impact of increased adherence on disease progression and further, the influence of 
this type of service in improving adherence and subsequent clinical biomarkers in a real 
world population.  The first-ever study in United Kingdom determining associations 
between adherence and clinical outcomes across the oral hypoglycaemic treatment 
paradigm in large general cohort of patients with type 2 diabetes was published in May 
2018 [271], after publishing the study from chapter two [387].  
 
6.1.1.2 Pharmacist gaining access to patient records will help in delivering better 
healthcare  
As discussed in the introductory chapter, many countries are recognizing the importance 
of improving medication adherence and have initiated services to improve adherence. At 
the time these MUR consultations were conducted the pharmacist had no access to any 
pathology data.  Recently, within New Zealand, there has been a change in the sharing of 
health information held by individuals.  This has increased the access that pharmacists 
have to laboratory results for people under their care [275]. Laboratory data / medical 
records shared with pharmacists may be advantageous to improve safety and avoid 
medication errors [276,277,278,279280]. This may allow the pharmacist to speak with 




the people directly about the importance of monitoring treatment efficacy or through the 
prescriber in a more collaborative care model.  This is important as often prescribers may 
be unaware of non-adherence and people may not feel comfortable disclosing it [270]. A 
closer working relationship between pharmacists and prescribers will have positive 
outcomes for people with diabetes and multimorbidity [281,282].  
6.1.1.2 Limitations of Medication Use Review study  
As the study relied on secondary data, not all information was available for all people. This 
also means that only people that were offered and accepted an MUR were included in this 
study. The adherence score given by the pharmacist is a non-validated tool and provides 
only an “estimation” of the individuals’ adherence as judged by the pharmacist conducting 
the MUR.  This scoring system appears blunt as it is assigned solely from the perspective 
of an MUR pharmacist. 
 
6.1.2 Feasibility study  
6.1.2.1 Validation of Pharmacist-generated MUR adherence score   
As mentioned in earlier studies, MUR adherence scores are subjective and were 
developed by the funders.  Given that there was no objective assessment conducted, it is 
very much determined by the pharmacists “impression” of the patient. The purpose of the 
validation study was to use both a subjective and objective measure to determine if the 
numbers assigned during a MUR reflected the actual adherence situation. Most of the MUR 
adherence scores were matching with the respective PDC values, thereby validating the 
pharmacist-generated adherence scores. However, there were some findings about 
under/over-estimation of MUR adherence scores as compared to PDC values. Such 




findings make a medication review programme warranted as a major limitation of PDC is 
the loss of information about the fate of drug after dispensing.        
6.1.2.2 Adherence support service and hospitalisation   
One study from chapter four found that hospital admission after a MUR visit decreased in 
35.9% of cases. This observation was consistent with the other studies reporting a drop 
in the rate of hospitalization after MUR or similar interventions [287,288,289,290]. The 
information obtained from hospitalisation records may help to determine the influence of 
medication review service (e.g. MUR).  However, this method using routinely-collected 
data to determine the clinical outcomes of MUR may not be feasible, as there is no direct 
correlation found between different adherence levels and rate of hospitalisation. Another 
limitation of this study was that it can provide a very basic comparison of a number of 
hospital admission before and after MUR consultation but the nature (reason) of 
hospitalization was not studied. The hospital admissions may not be related to diabetes 
(or the disease/disorder for which MUR consultation was given). Data collected at the 
time of hospitalisation is recorded for a specific purpose (i.e treatment diagnosis and 
pathway).  If the recording of this information was made inclusive, (i.e. underlying 
conditions), by evaluating why they were admitted, it may be possible to infer a drug 
related problem (DRP), but the DRP may not be just the diabetes medication. 
 
6.1.3 Oral hypoglycaemic dispensing and drug burden within a single New 
Zealand locality   
Healthcare use, accessibility, or population may be increased in the Bay of Plenty DHB, 
New Zealand over a study period of eight years as the number of patients in the 




Pharmhouse dispensing records kept rising every year, as did the count of OHG 
dispensing (Appendix D). The OHG dispensing was higher in male patients, in NZ Māori 
and in Indians which coincides with the findings of the prevalence of diabetes in 
indigenous peoples around the globe [321,322]. As T2DM was found to be more prevalent 
in lower SES, and people from the developed (high-income) countries 
[340,341,342,343,344], this study also revealed that the lower income group patients 
(socioeconomic deprivation index 8-10) had significantly (P<0.001) higher rates of OHG 
dispensing.   
The further analysis of prevalence and co-prevalence of co-dispensing in OHG patients, 
found that 88.5% of the patients presented with co-dispensing. Co-dispensing was 
significantly higher in male patients and the NZ European ethnic group. The count of co-
dispensed medications ranged from 1 to 6 medications. Co-dispensing was highly 
correlated to older age and this finding supports the similar observation from other 
studies [345,347,348,349,350,351]. High rates of co-dispensing indicate the presence of 
multiple comorbidities. Such situations of concomitant therapies may contribute to 
increased treatment complexity, additional healthcare expenses and pill burden which 
may affect the quality of life and may trigger psycho-social disorders [370,371,372,373]. 
 
6.1.4 Medication adherence using pharmacy administrative data   
Medication non-adherence is a preventable public health burden if identified and 
corrected early [148]. Therefore, identification of medication non-adherence (prevalence, 
nature/cause) is the most important step for developing the strategies for adherence 
improvement [239]. Despite the availability of different methods of adherence estimation, 




there are no gold standards. Determination of the adherence level within the large 
population (real-world) is especially challenging. Different methods available have their 
own advantage and drawback as they are based on the source of data and conditions of 
data collection. For accurate adherence measurement, these methods should be reliable, 
change sensitive and validated [63,142]. One study from chapter five aimed to identify the 
level of medication adherence in patients taking oral hypoglycemics (OHG) from a 
particular locality in New Zealand. This study preferred the proportion of days covered 
(PDC) as a surrogate marker for estimating medication adherence using pharmacy 
dispensing records, as PDC is a validated and time-tested quality measure [106] for 
medication adherence calculation in a population. This accurately reflects patient 
adherence behaviour and effectively handles drug switching and prescription overlaps 
[98,99]. Also, it is well recommended by Pharmacy Quality Alliance (PQA) & The Centers 
for Disease Control and Prevention (CDC) (the recognized institutes in the USA working 
for public health benefits and promoting appropriate medication use [106]).  
6.1.4.1 Oral hypoglycaemic medication adherence within a single New Zealand 
locality   
The results from this study reported non-adherence (PDC <80%) in 54.5% patients taking 
OHG in the study region (Bay of Plenty, DHB). These results are consistent with the other 
studies reporting significant medication non-adherence with oral hypoglycaemics 
therapy [129,243,307,428,429]. Non-adherence (PDC < 80%) was significantly higher in 
the NZ Māori ethnic group, in young and the middle aged (21 to 60 years) and in patients 
with low socioeconomic status. Race and socioeconomic disadvantage are coexistent 
factors for non-adherence [398]. Lower adherence rates in African-American patients 




were reported as compared with white patients [399,400]. These observations are similar 
to the non-adherence observed in the NZ Māori ethnic group as compared to NZ 
Europeans. 
Interestingly the patients over 60 years of age showed reasonable adherence to OHG 
therapy. Other studies have also shown that that adherence can be better in older patients 
[406].  This may be due to them becoming accustomed to their medications as they are 
taking it for a long time, and such an established routine reminds them to take medication 
on time [407]. 
6.1.4.2 Factors associated with Oral hypoglycaemic medication adherence 
One study from chapter five observed a higher rate of non-adherence in OHG patients who 
were subjected to treatment alteration, either by replacing the existing OHG drug or by 
the addition of a new OHG drug to existing regimen. The spread of non-adherence was 
notably higher in OHG therapy with a combination of two (77.4%) & three (93.3%) than 
monotherapy (42.2%). The daily doses of two or more OHG tablets were associated with 
a higher non-adherence level than the single daily dose.  
Treatment modifications are inevitable in the case of poor therapeutic outcomes by 
existing regimen [410]. Drug shift during the course of the treatment may create some 
confusion in patients about the use of a drug or a lack of knowledge of its effectiveness 
[411]. Also the change or addition of a new drug to a treatment is not always well received 
by patients as it may lead to adverse events/side effects [411]. This may discourage 
patients from refilling the prescription or they may completely stop consuming them 
[412]. Poorer medication adherence in chronic treatment can be related to multiple daily 
dosing [414,430].  




Multiple comorbidities comprising chronic illnesses (e.g. cardiovascular, mental, diabetes 
etc.) joint pains, acute conditions (e.g. viral infections) are prevalent in older age groups 
[345,346]. Hence, medication count is higher in older patients as compared to young or 
middle-aged adult patients [345,346,347]. Polypharmacy related medication non-
adherence in older population is well documented in academic research 
[66,67,68,69,70,71,72,73]. The results from this thesis support the findings from the 
above-mentioned studies, except for polypharmacy in elderly patients. 
This thesis observed that polypharmacy (5-9 medication) and excess polypharmacy (10 
or more medications) was significantly higher in older patients (age 61 years and above). 
Many published studies reported non-adherence in patients with polypharmacy 
[124,125,230,415,416,417,418,419]. Contrary to these studies, the current study 
observed that there was an increased adherence in patients with polypharmacy and 
excess polypharmacy. This could be because older patients or patients on multiple 
medications or older patients with complex drug regimens are mostly subjected to 









6.2 General conclusion  
Adherence support services can improve medication adherence in the real world 
population. These services do have a positive influence on clinical outcomes and which 
can be seen as changes in the clinical biomarkers.  
 The use of routinely collected health information (hospitalisation and pharmacy 
collection data) for the long term evaluation of MUR service was found to be feasible.  The 
MUR pharmacists should also check patient’s dispensing history to reflect on the actual 
adherence situation. 
Not all patients can receive adherence support services, so the use of a large dataset (e.g. 
pharmacy collection data) may provide insights into how widespread the adherence 
issue is and how many may benefit from such a service. Though the calculation of 
proportion of days covered (PDC) as a surrogate adherence marker is a validated and 
time-tested quality measure, the major limitation of this method is failure to capture the 









6.3 Future scope 
Insights for physician/clinicians:  
A study from chapter one found that very few people received testing as frequently as 
suggested in the guidelines.  This is an area worthy of further investigation: whether the 
prescribers are not requesting the tests, or whether people are not actioning the requests. 
This thesis also found that a higher medication count and multiple daily dosing may lead 
to medication non-adherence. Hence, before the intensification of OHG, optimization of 
monotherapy should be started. The remaining life expectancy of older patients need to 
be considered while prescribing additional medication. Adherence support services 
should not only be offered to older patients as young/adults were also found to be non-
adherent. 
 
Insights for MUR pharmacist: 
Most of the patients failing in follow-up MUR visits were either poor or non-adherent. An 
important observation was that even many patients with good or complete adherence 
failed to revisit. They should be further evaluated to identify the reasons for the failure of 
a follow-up visit. A single MUR visit might not be enough and so the multiple follow-up 
visits should be encouraged to achieve desired outcomes. Most of the literature showed 
that MUR services are offered to an older patient but this thesis found out that there was 
a large number of non-adherent patients from the middle-aged range who could benefit 
from such services. 
 
 




Insights for policy makers: 
One clear finding from the present research is that therapeutic influence of adherence 
support service can be tracked by assessing clinical biomarkers. Hence, laboratory data / 
medical records shared with pharmacists may be advantageous to improve safety and 
avoid medication errors. A closer working relationship between pharmacists and 
prescribers will have positive outcomes for people with diabetes and multimorbidity. 
One surprising finding from the chapter two study was the identification of a group of 
people who had significantly elevated HbA1c levels and no treatment with oral 
hypoglycemic initiated during the period of this study. Access to pathology data within a 
pharmacy may allow a more tailored conversation and goal setting to achieve the desired 
therapeutic outcomes in the patients. Again a multidisciplinary approach and shared 




The observations from chapter four and five were focused only on the use of oral 
hypoglycemics. The use of other important medications in the large population sample 
(e.g. cardiovascular agents, psychotherapeutic agents, anticancer agents etc.) can be 
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Appendix A: Medication review services in different countries 
A1 Medication Therapy Management (MTM), Unites States of America (USA) 
[214,215] 
In the USA, under the Medicare Modernization Act of 2003, pharmacist-led medication 
therapy management (MTM) services were included in Medicare Part D prescription 
drug plans from the year 2006. 
A1.1 The aim of MTM service, USA 
Medication Therapy Management aims to address the urgent public health need for the 
prevention of medication-related morbidity and mortality, to contribute to medication 
error prevention, result in improved reliability of health care delivery, and enable 
patients to take an active role in medication and health care self-management, to enhance 
patient understanding of appropriate drug use, and increase adherence to medication 
therapy. 











A2 Medicines Use Review, United Kingdom (UK) [216] 
In the UK the Medicines Use Review (MUR) service was introduced in April 2005 as the 
first advanced service for community pharmacy. 
A2.1 The aim of MUR service, UK 
The Medicines Use Review (MUR) aims to help patients use their medicines more 
effectively. Following the review, recommendations made to prescribers may also relate 
to the clinical or cost-effectiveness of the treatment. The service includes Medicines Use 
Reviews taken periodically or when there is a need to make an adherence-focused 
intervention due to a problem that is identified while providing the dispensing service (a 
prescription intervention MUR). 
There are two types of MUR: 
 Planned MUR – this occurs when the patient is invited for a consultation. It can 
be conducted for patients on multiple medicines and those with long-term 
conditions. 
 Intervention MUR (or prescription intervention MUR) – this is an MUR 
conducted around dispensing in response to a significant problem with a 
patient’s adherence to a medicine, for example when a patient needs to develop 
their understanding of their medicines in order to improve use. The pharmacist 
will need to decide whether or not the intervention is clinically significant and 
requires more than brief advice. Dose optimization and synchronization of 









A3 MedsCheck program, Canada [217] 
The Ministry of Health and Long-Term Care (the “ministry”), collaboratively with the 
Ontario Pharmacy Council and the Ontario Pharmacists Association launched the 
MedsCheck program on April 1st, 2007, as the first professional pharmacy service in 
Ontario. 
A3.1 The aim of the MedsCheck program, Canada [217] 
The MedsCheck program aims to be a standardized approach to assess a patient’s ability 
to administer their medications; appropriateness of the medication and dosing intervals; 
potential interactions, side effects, drug allergies and contraindications; and includes 
communication with the physician and/or health care professionals to resolve potential 
drug therapy problems that are identified using the guidelines outlined in the 
Pharmaceutical Opinion Program.  
 
A4 Home medication review (HMR), Australia [218,219,220] 
In Australia, a Home Medicines Review (HMR) service was introduced into the Medical 
Benefits Schedule (MBS) in October 2001. 
A4.1 The aim of HMR service, Australia 
The HMR is a consumer-focused, structured and collaborative health care service 
provided in the community setting, aiming to optimize the quality use of medicines and 
consumer understanding. It involves the consumer, their general practitioner (GP), an 
accredited pharmacist, and the consumer’s regular pharmacy, along with any other 
relevant members of the health care team.  HMR aimed to assist consumers living in the 







Figure A4: Home medication review (HMR) model in Australia [220]. 
 
The characteristics of the pharmacist-led medication review services across different 
countries are highlighted in Table A. The eligibility of a patient to get enrolled for the 
medication review service varies based on the country of origin and the nature of the 






Table A: Comparison of the pharmacist-led medication review services across USA, UK, Canada & Australia 
MTM, USA [214,215] MUR, UK [216] MedsCheck, Canada [217] HMR, Australia [218,219,220] 
The goal for the patient 
Evaluating patient’s health, 
ongoing treatment, medication-
taking behaviour and risk-benefit 
ratio of multiple medication 
regimen. To find, reconcile and 
avoid adherence issue or drug-
related problems by conducting 
an extensive medication review. 
To improve medication’s use by 
developing patient understanding. 
Integration of prescribed items and 
dose optimization in patients with 
long-term conditions and complex 
drug regimen. To improve 
medication adherence and reduce 
medicine wastage. 
To endorse disease self-
management, healthier outcomes 
and quality of life through patient 
education. To optimize the 
effectiveness and safety of drug 
therapy and to improve 
treatment adherence. 
To achieve better health 
outcomes for consumers living at 
home by optimizing medication, 
by identifying and acting on 
adherence problems and/or 
issues related to safety and 
effectiveness (adverse events) of 
medication. 
The goal for the healthcare system  
To enhances communication 
between patient and their 
healthcare team. To optimize 
medication use in accordance 
with evidence-based guidelines 
by collaborative work from 
pharmacists, physicians, and 
other healthcare professionals. 
To share information about the 
pharmacist-led MUR intervention 
with other prescribers or healthcare 
providers for effective medication 
management. To develop a joint 
action plan for the issues identified 
beyond the scope of the MUR service 
or pharmacist. 
To support patient access to 
health care services and 
resources. To promote system 
efficiency and ensure health 
resources are used appropriately. 
To communicate patient 
information and support 
interdisciplinary collaboration in 
patient care. 
To facilitate cooperative working 
relationships between members 
of the health care team in the 
interests of consumer health and 
well-being. To improve health 
professional knowledge and 






Table A (continued): Comparison of the pharmacist-led medication review services across USA, UK, Canada & Australia 
MTM, USA [214,215] MUR, UK [216] MedsCheck, Canada [217] HMR, Australia [218,219,220] 
Accreditation of pharmacist providing the service 
A registered pharmacist.  
(No mention of any other  
special certificate or  
training requirement). 
A registered pharmacist with an 
MUR certificate approved by the 
NHSCB [NHS England].  
Pharmacist registered to practice 
direct patient care with the 
Ontario College of Pharmacists 
(OCP) (Part A of the Register, 
OCP). Pharmacists are 
encouraged to have training or 
certification in geriatrics. 
 
A registered pharmacist with 
medication reviews accreditation 
obtained from the Australian 
Association of Consultant 
Pharmacy (AACP) or The Society 
of Hospital Pharmacists of 
Australia (SHPA) and who have 
completed the appropriate level 
of training. 
Review service referrals  
Patients can be referred from 
many sources including, but not 
limited to, pharmacist 
identification, physician referral, 
patient self-referral, and health 
plan or other payer referral. 
Patients may self-refer into the 
service and other referrals may 




A patient’s family physician, a 
specialist or a registered nurse in 
the extended class 
[RN(EC)]/nurse practitioner 
(NP) may refer a patient for a 
MedsCheck. 
Self-referral by the patient. 
Referral by a general practitioner 
or community pharmacist or 
hospital pharmacist at hospital 
discharge or another member of 






Table A (continued): Comparison of the pharmacist-led medication review services across USA, UK, Canada & Australia 
MTM, USA [214,215] MUR, UK [216] MedsCheck, Canada [217] HMR, Australia [218,219,220] 
Eligibility of patient for service enrolment 
Any patients using prescription 
and non-prescription 
medications, herbal products, 
and other dietary supplements 
could potentially benefit from 
medication therapy management 
(MTM) services. Patients may be 
evaluated for MTM services 
regardless of the number of 
medications they use, their 
specific disease state(s), or their 
health plan coverage. 
Patients who have received 
pharmaceutical services from the 
community pharmacy for a 
period of at least three 
consecutive months. Patients 
who have one or less MUR 
consultation in any 12-month 
period unless pharmacist 
recommends one (or more) 
further consultations during that 
period.  
Any Ontarian with a valid Ontario 
Health Card, living in Ontario and 
on a minimum of three 
prescription medications for 
chronic conditions. 
To be eligible for an HMR, a 
consumer must hold a current 
Medicare card, or Department 
of Veterans' Affairs (DVA) card in 
the case of war veterans, widows 
and widowers, and be living in 
the community (including respite 
care). HMR services are not 
available to in-patients of public 
or private hospitals, day hospitals 
or aged care facilities. 
Medication review service can be offered to the patient with one or more conditions enlisted below: 
1) taking multiple medications (five or more), 2) have multiple prescribers, 3) suffering from one or more chronic illness, 4) not responding 
to the prescribed therapy, 5) exhibit medication non-adherence, 6) has limited health literacy or cultural differences, 7) taking narrow 
therapeutic index drugs or high-risk medication(s), 8) significant changes to medication regimen, 9) recent discharge from a hospital and 10) 






Table A (continued): Comparison of the pharmacist-led medication review services across USA, UK, Canada & Australia 
MTM, USA [214,215] MUR, UK [216] MedsCheck, Canada [217] HMR, Australia [218,219,220] 
Settings for conducting medication review  
MTM services should be 
delivered face to face in a private 
or semi private area, as required 
by the Health Insurance 
Portability and Accountability 
Act, by a pharmacist whose time 
can be devoted to the patient 
during this service.  
In other patient-care settings 
(e.g., acute care, long-term care, 
home care, managed care), the 
environment in which MTM 
services are delivered may differ 
because of variability in structure 
and facilities design. An 
alternative method (e.g. 
telephonic) may be used if 
needed. 
At the pharmacy or general 
practitioner premises provided 
with a designated area for 
confidential consultation 
distinctly away from general 
public areas.  
At a specific care home or nursing 
home. At the patient’s home. 
Occasionally over the telephone 
where the telephone 
conversation cannot be 
overheard. 
Medication review conducted in 
person (through one-on-one 
interactions) at an accredited 
community pharmacy. Interview 
setting must ensure patient 
privacy.  
Cannot conduct service over the 
phone or through video 
conferencing. 
It is considered best practice for 
the HMR interview to take place 
in the consumer’s home. 
However, there may be occasions 
when the consumer’s preference, 
due to cultural and/or due to 
safety concerns, requires the 
interview takes place in a location 














































2008 156832 151875 4957 Nil Nil Nil Nil 
2009 163996 158467 5529 4352 78.7 1177 21.3 
2010 170423 164400 6023 4870 80.9 1153 19.1 
2011 175496 169105 6391 5248 82.1 1143 17.9 
2012 177247 170610 6637 5533 83.4 1104 16.6 
2013 179651 172753 6898 5763 83.5 1135 16.5 
2014 183923 176689 7234 5957 82.3 1277 17.7 

















Appendix E: The percentage dispensing for each class of the drug during the study 
period. 
Class of medication Count % 
OHG 482110 23.4 
Statins 242266 11.7 
ACE inhibitors 167737 8.1 
Beta blockers 125566 6.1 
PPIs 103355 5 
Antiplatelet agents 103903 5 
Pyridine Ca channel blockers 82031 4 
Loop diuretics 72198 3.5 
Antigout 52935 2.6 
ACE inhi. + Diuretics 46653 2.3 
Angio II blockers 40657 2 
Other Ca channel blockers 38018 1.8 
SSRIs 35149 1.7 
Alpha blockers 31374 1.5 
Thiazide diuretics 26531 1.3 
Nitrates 24391 1.2 
Non-opioid Analgesics 25691 1.2 
Cyclic and Related Agents 21986 1.1 
Thyroid and Antithyroid Agents 21846 1.1 
General anaesthetics 19487 0.9 
Antiarrhythmics 16016 0.8 
Iron 15720 0.8 
Anti epilepsy 15842 0.8 
Calcium 15125 0.7 
Faecal Softeners 13646 0.7 
Vit.D 14787 0.7 
Fibrates 11552 0.6 





Oral administration 11896 0.6 
Sedatives and Hypnotics 11777 0.6 
Class of medication Count % 
Other Urinary Agents 11969 0.6 
Opioid Analgesics 11316 0.5 
NSAIDs 9806 0.5 
Multivitamins 7879 0.4 
Antihistamines 8375 0.4 
Corticosteroids Systemic Use 9130 0.4 
Penicillins 7611 0.4 
H2 blocker antacids 5979 0.3 
Oral anticoagulants 6684 0.3 
Anxiolytics 6440 0.3 
Anti emetics 5217 0.3 
Cholest. Abspn. Inhi. 4104 0.2 
Vit.B 4081 0.2 
Megaloblastic 4756 0.2 
Other Antidepressants 4828 0.2 
Alendronate for Osteoporosis 5083 0.2 
K sparing combo diuretics 1655 0.1 
Centrally-Acting agents 1138 0.1 
Angio II blockers + Diuretics 2779 0.1 
Alpha glucosidase inhi. 2596 0.1 
GI motility inhi. 1204 0.1 
Rectal anti-inflammatory 1401 0.1 
Vit. C 1351 0.1 
Dopamine agonists 2333 0.1 
Anticholinergics 1495 0.1 
Antirheumatoid Agents 1080 0.1 
Muscle Relaxants 1597 0.1 
Methylxanthines 1071 0.1 
Antiprotozoals 2694 0.1 





Other Antibiotics 1740 0.1 
Tetracyclines 1882 0.1 
Class of medication Count % 
Cephalosporins and Cephamycins 1427 0.1 
Urinary Tract anti Infectives 1257 0.1 
5-Alpha Reductase Inhibitors 1424 0.1 
Antimetabolites 1126 0.1 
Endocrine Therapy 1756 0.1 
Aromatase Inhibitors 1881 0.1 
Other anti-lipids 186 0 
Stimulant laxatives 883 0 
Antispasmodics 612 0 
Digestive enzymes 474 0 
Antacids 7 0 
Phosphate binding antacids 259 0 
Zinc 765 0 
Oropharyngeal Anti-infectives 104 0 
Anti H.Pylori 26 0 
Haemostatics 105 0 
Vit. K 7 0 
Acute Migraine Treatment 136 0 
Anti Substance Dependence 384 0 
MAO-A inhibotors 430 0 
Stimulants/ADHD treatments 73 0 
MAO inhibitors 41 0 
Migraine prophylaxis 178 0 
NSAIDs Other 50 0 
Other muscle Treatments 262 0 
Beta-Adrenoceptor Agonists 10 0 
Oestrogens 285 0 
Other Oestrogen Preparations 346 0 





Progestogen + Oestrogen 
Preparations 
189 0 
Class of medication Count % 
Androgen Agonists and 
Antagonists 
265 0 
Progestogens 228 0 
Vasopressin Agonists 1 0 
Other Endocrine Agents 34 0 
Hepatitis B Treatment 205 0 
Antifungals 600 0 
Antitrichomonal Agents 187 0 
Herpesvirus Treatments 402 0 
Non-NRT Inhibitors antiviral 30 0 
NRT Inhibitors antiviral 37 0 
Anti TB & Antileprotics 127 0 
Anthelmintics 4 0 
Psoriasis and Eczema 
Preparations 
259 0 
Antiandrogen Oral Contraceptives 321 0 
Combined Oral Contraceptives 165 0 
Progestogen-only Contraceptives 68 0 
Glaucoma Preparations - Carbonic 
Anhydrase Inhibitors 
116 0 
Other Cytotoxic Agents 454 0 
Alkylating Agents 34 0 
Cytotoxic Immunosuppressants 256 0 
Other Immunosuppressants 271 0 
Removal and Elimination 25 0 
Total 2062119 100 
 
